Spectrum Pharmaceuticals (SPPI) 10-K13 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Feb. 28, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	SPPI
Entity Registrant Name	SPECTRUM PHARMACEUTICALS INC
Entity Central Index Key	831547
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		66,871,240
Entity Public Float			$534,392,193

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$129,942	$156,306
Marketable securities	3,306	3,471
Accounts receivable, net of allowance for doubtful accounts of $120 and $206, respectively	70,758	49,483
Other receivables	5,489	7,539
Inventories	9,200	13,519
Prepaid expenses	3,774	3,213
Deferred tax assets		1,659
Total current assets	222,469	235,190
Property and equipment, net of accumulated depreciation	1,405	1,535
Intangible assets, net of accumulated amortization	230,100	231,352
Goodwill	18,195	18,501
Other assets	17,864	12,577
Total assets	490,033	499,155
Current liabilities:
Accounts payable and other accrued liabilities	84,994	79,837
Accrued payroll and benefits	8,444	6,872
Deferred revenue	9,959	156
Drug development liability	1,141	3,119
Acquisition related contingent obligations	4,901
Total current liabilities	109,439	89,984
Drug development liability, less current portion	14,644	14,623
Acquisition-related contingent obligations	2,441	8,329
Deferred tax liability	6,569	7,168
Other long-term liabilities	6,088	5,965
Convertible senior notes	96,298	91,480
Total liabilities	235,479	217,549
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value; 175,000,000 shares authorized; 65,969,699 and 64,104,173 issued and outstanding at December 31, 2014 and 2013, respectively	66	64
Additional paid-in capital	538,553	518,144
Accumulated other comprehensive (loss) income	-850	894
Accumulated deficit	-283,338	-237,619
Total stockholders' equity	254,554	281,606
Total liabilities and stockholders' equity	490,033	499,155
Series E Convertible Voting Preferred Stock [Member]
Stockholders' equity:
Preferred stock	$123	$123

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts receivable	$120	$206
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued	65,969,699	64,104,173
Common stock, shares outstanding	65,969,699	64,104,173
Series B Junior Participating Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series E Convertible Voting Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, stated value	$10,000	$10,000
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	20	20
Preferred stock, shares outstanding	20	20
Convertible preferred shares	40,000	40,000
Preferred stock, liquidation value	$240	$240

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product sales, net	$186,537	$143,475	$254,992
License fees and service revenue	293	12,379	12,715
Total revenues	186,830	155,854	267,707
Operating costs and expenses:
Cost of product sales (excludes amortization of intangible assets)	27,037	28,580	46,633
Selling, general and administrative	97,412	99,315	89,922
Research and development	69,662	46,670	41,560
Amortization and impairment of intangible assets	24,288	20,074	8,818
Total costs and operating expenses	218,399	194,639	186,933
(Loss) income from operations	-31,569	-38,785	80,774
Other (expense) income:
Interest expense, net	-8,584	-2,192	-485
Change in fair value of contingent consideration related to acquisitions	987	2,871	-20
Other (expense) income, net	-4,367	1,470	-359
Total other (expense) income	-11,964	2,149	-844
(Loss) income before income taxes	-43,533	-36,636	79,930
(Provision) benefit for income taxes	-2,186	-25,498	14,271
Net (loss) income	($45,719)	($62,134)	$94,201
Net (loss) income per share:
Basic	($0.71)	($1.02)	$1.61
Diluted	($0.71)	($1.02)	$1.46
Weighted average shares outstanding:
Basic	64,708,163	60,729,128	58,588,916
Diluted	64,708,163	60,729,128	64,637,256

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net (loss) income	($45,719)	($62,134)	$94,201
Other comprehensive (loss) income, net of tax:
Unrealized (loss) gain on available-for-sale securities	-1,122	690	584
Adjustment for realized gain on available-for-sale securities, and included in net income	-2,217
Foreign currency translation adjustments	1,595	-69	-84
Other comprehensive (loss) income, net	-1,744	621	500
Total comprehensive (loss) income	($47,463)	($61,513)	$94,701

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total Stockholders Equity [Member]
In Thousands, except Share data	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total Stockholders Equity [Member]
Beginning Balance at Dec. 31, 2011		$123	$59	$452,761	($227)	($257,704)	($2,926)	$192,086
Beginning Balance, Shares at Dec. 31, 2011		20	59,247,483				363,055
Net income (loss)	94,201					94,201		94,201
Other comprehensive Income (loss), net	94,701				500			500
Issuance of common stock to 401(k) plan				691				691
Issuance of common stock to 401(k) plan, Shares			56,254
Issuance of common stock for ESPP				606				606
Issuance of common stock for ESPP, Shares			54,521
Issuance of common stock upon exercise of stock options			2	5,815				5,817
Issuance of common stock upon exercise of stock options, Shares	1,287,430		1,287,430
Issuance of common stock upon exercise of warrant				89				89
Issuance of common stock upon exercise of warrant, Shares			50,000
Share-based compensation expense and common stock issued (net of forfeitures)				14,193				14,193
Share-based compensation expense and common stock issued (net of forfeitures), Shares			554,239
Repurchase of shares to satisfy employee tax withholding				-1,434				-1,434
Repurchase of shares to satisfy employee tax withholding, Shares			-120,197
Dividends paid				-9,011				-9,011
Purchase of treasury stock							-9,057	-9,057
Purchase of treasury stock, Shares							740,000
Retirement of treasury stock	-11,983		-1			-11,982	11,983
Retirement of treasury stock, Shares			-1,103,055				-1,103,055
Ending Balance at Dec. 31, 2012		123	60	463,710	273	-175,485		288,681
Ending Balance, Shares at Dec. 31, 2012		20	60,026,675
Net income (loss)	-62,134					-62,134		-62,134
Other comprehensive Income (loss), net	-61,513				621			621
Issuance of common stock to 401(k) plan				860				860
Issuance of common stock to 401(k) plan, Shares			99,359
Issuance of common stock for ESPP				495				495
Issuance of common stock for ESPP, Shares			74,925
Issuance of common stock upon exercise of stock options			1	3,576				3,577
Issuance of common stock upon exercise of stock options, Shares	825,884		825,884
Share-based compensation expense and common stock issued (net of forfeitures)				11,193				11,193
Share-based compensation expense and common stock issued (net of forfeitures), Shares			471,875
Repurchase of shares to satisfy employee tax withholding				-1,509				-1,509
Repurchase of shares to satisfy employee tax withholding, Shares			-159,545
Purchase of treasury stock							-1,651	-1,651
Purchase of treasury stock, Shares							235,000
Retirement of treasury stock	-1,652			-1,651			1,651
Retirement of treasury stock, Shares			-235,000				-235,000
Issuance of common stock for Talon acquisition			3	26,307				26,310
Issuance of common stock for Talon acquisition, Shares			3,000,000
Issuance of 2018 Convertible Notes				14,443				14,443
Ending Balance at Dec. 31, 2013		123	64	518,144	894	-237,619		281,606
Ending Balance, Shares at Dec. 31, 2013	64,104,173	20	64,104,173
Net income (loss)	-45,719					-45,719		-45,719
Other comprehensive Income (loss), net	-47,463				-1,744			-1,744
Issuance of common stock to 401(k) plan				1,028				1,028
Issuance of common stock to 401(k) plan, Shares			133,734
Issuance of common stock for ESPP				639				639
Issuance of common stock for ESPP, Shares			99,551
Issuance of common stock upon exercise of stock options			1	1,905				1,906
Issuance of common stock upon exercise of stock options, Shares	485,260		485,260
Share-based compensation expense and common stock issued (net of forfeitures)				10,781				10,781
Share-based compensation expense and common stock issued (net of forfeitures), Shares			396,083
Repurchase of shares to satisfy employee tax withholding				-1,733				-1,733
Repurchase of shares to satisfy employee tax withholding, Shares			-249,102
Issuance of common stock to TopoTarget for milestone achievement			1	7,789				7,790
Issuance of common stock to TopoTarget for milestone achievement, Shares			1,000,000
Ending Balance at Dec. 31, 2014		$123	$66	$538,553	($850)	($283,338)		$254,554
Ending Balance, Shares at Dec. 31, 2014	65,969,699	20	65,969,699

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities:
Net (loss) income	($45,719)	($62,134)	$94,201
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Amortization of deferred revenue		-12,400	-12,300
Depreciation and amortization	25,352	22,096	12,243
Stock-based compensation	11,809	12,423	14,884
Change in fair value of common stock warrants issued to non-employees		356
Accretion of debt discount to interest expense on 2018 Convertible Notes (Note 13)	4,818	43
Amortization of deferred financing costs to interest expense on 2018 Convertible Notes (Note 13)	599	101
Bad debt (recovery) expense	-85	127	-128
Loss on disposal of fixed assets			132
Non-cash foreign currency exchange loss	6,033	1,222	107
Impairment of intangible assets		1,023
Change in fair value of contingent consideration related to acquisitions (Note 10)	-987	-2,871	20
Change in fair value of Allos deferred development costs and deferred payment contingency (Note 14)		-2,869
Value of stock issued to Topo-Target for milestone achievement, recognized as research and development expense	7,790
Changes in operating assets and liabilities:
Accounts receivable, net	-21,671	42,559	-33,504
Other receivables	2,070
Inventories	4,253	1,570	3,530
Prepaid expenses and other current assets	-718	-359	9,483
Deferred tax assets	1,724	33,252	-34,605
Other assets	-13,161	-8,989
Accounts payable and other accrued obligations	5,304	-23,897	24,038
Accrued payroll and benefits	1,594	425	-9,726
Drug development liability	-1,957	-5,917	2,376
Deferred revenue	9,803
Deferred tax liability	-602
Other long-term liabilities	124	2,153	1,208
Net cash (used in) provided by operating activities	-3,627	-2,086	71,959
Cash Flows From Investing Activities:
Sales and maturities of marketable securities			72,463
Purchases of marketable securities			-26,430
Purchases of property and equipment	-934	-161	-312
Purchases of available-for-sale securities			-1,712
Proceeds from sale of available-for-sale securities	4,093
Acquisition of Allos, net of cash acquired (Note 10)			-133,264
Net cash (used in) provided by investing activities	-21,841	-14,330	-114,690
Cash Flows From Financing Activities:
Proceeds from Mundipharma related to FOLOTYN collaboration (Note 14)		7,000
Proceeds from exercise of stock options	1,906	3,576	5,817
Proceeds from exercise of common stock warrants			89
Proceeds from sale of stock under employee stock purchase plan	639	495	606
Purchase of treasury stock		-1,651	-9,057
Purchase and retirement of restricted stock to satisfy employee tax liability at vesting	-1,733	-1,509	-1,434
Payment of stock dividend			-9,011
Repayment of capital leases			-9
Proceeds from revolving line of credit (Note 12)		100,000	125,000
Repayment of revolving line of credit (Note 12)		-175,000	-50,000
Proceeds from 2018 Convertible Notes (Note 13)		120,000
Deferred financing costs (Note 13)		-4,573
Proceeds from sale of common stock warrants for 2018 Convertible Notes issuance (Note 13)		12,612
Payment of debt issuance costs (Note 13)			-976
Purchase of common stock call options related to 2018 Convertible Notes issuance (Note 13)		-25,692
Net cash provided by (used in) financing activities	812	35,258	61,025
Effect of exchange rates on cash and equivalents	-1,708	-2,235	202
Net (decrease) increase in cash and equivalents	-26,364	16,608	18,496
Cash and equivalents - beginning of year	156,306	139,698	121,202
Cash and equivalents - end of year	129,942	156,306	139,698
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes	329		17,157
Cash paid for interest	3,227	1,200	495
Retirement of treasury shares		1,652	11,983
Inventory liability assumed in acquisitions			580
Inventory included in accounts payable			5,000
ZEVALIN Ex-U.S. Distribution Rights [Member]
Cash Flows From Investing Activities:
Acquisition of Allos, net of cash acquired (Note 10)			-25,435
C-E MELPHALAN rights [Member]
Cash Flows From Investing Activities:
Acquisition of Allos, net of cash acquired (Note 10)		-3,000
Talon [Member]
Cash Flows From Investing Activities:
Acquisition of Allos, net of cash acquired (Note 10)		-11,169
Supplemental Disclosure of Cash Flow Information:
Common stock issued for acquisition		26,310
BELEODAQ [Member]
Cash Flows From Investing Activities:
Capitalized milestone payment upon FDA approval of BELEODAQ	($25,000)

Description_of_Business_Basis_

Description of Business, Basis of Presentation, and Operating Segment	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	1. DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT
	(a) Description of Business
	Spectrum Pharmaceuticals, Inc. and its subsidiaries and other consolidated entities (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biotechnology company, with a primary focus in oncology and hematology. Our strategy is comprised of the (i) commercialization of cancer therapeutics through our U.S. direct sales force and international distributors, (ii) completion of studies for new indications of our marketed products, and (iii) acquisition, development and marketing of a broad and diverse pipeline of late-stage clinical and commercial drug compounds.
	We currently market five drugs for the treatment of cancer:

		•	FUSILEV injection for patients with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

		•	ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma;

		•	FOLOTYN injection for patients with relapsed or refractory PTCL;

		•	MARQIBO injection for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia; and

		•	BELEODAQ® injection for patients with relapsed or refractory PTCL (launched in July 2014).
	We also have ongoing indication expansion studies with several of our marketed products, and a diversified pipeline of product candidates in Phase 2 and Phase 3 clinical studies.
	(b) Basis of Presentation
	Principles of Consolidation
	The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned (except for SPC, as discussed below). All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.
	Variable Interest Entity
	We own fifty-percent of Spectrum Pharma Canada (“SPC”), organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this “variable interest entity” (as defined under applicable GAAP). We are obligated to fund all of SPC’s costs and have the sole rights to any revenue it derives. Since we carry the full risks and rewards of SPC, we meet the criteria of being its “primary beneficiary.” Accordingly, SPC’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.
	(c) Operating Segment
	We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2014, 2013, and 2012, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our assets (excluding certain of our bank accounts and intangible asset rights held by our wholly-owned foreign subsidiaries) are located in the U.S.

Summary_of_Significant_Account

Summary of Significant Accounting Policies and Use of Estimates	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Use of Estimates	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES
	The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, our management evaluates its estimates, including those related to (i) gross-to-net revenue adjustments; (ii) the collectability of customer accounts; (iii) whether the cost of inventories can be recovered; (iv) the fair value of goodwill and intangible assets; (v) the realization of tax assets and estimates of tax liabilities; (vi) the likelihood of payment and value of contingent liabilities; (vii) the fair value of investments; (viii) assumptions used in reporting stock-based compensation; and (ix) the potential outcome of ongoing or threatened litigation.

	Our estimates are based on our management’s professional judgment which involves their experience and consideration of all available facts. Actual results may materially differ from management’s estimates. In our management’s judgment, the accounting policies, estimates, and assumptions described below have the greatest potential to significantly impact the accompanying Consolidated Financial Statements:
	(i) Revenue Recognition
	(a) Product Sales: We sell our products to wholesalers or distributors (i.e., our customers), except for our U.S. sales of ZEVALIN in which case the end-user (i.e., clinic or hospital) is our customer. Our wholesalers and distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized when title and risk of loss have transferred to our customer, and the following additional criteria are met:

		-1	appropriate evidence of a binding arrangement exists with our customer;

		-2	price is substantially fixed and determinable;

		-3	collection from our customer is reasonably assured;

		-4	our customer’s obligation to pay us is not contingent on resale of the product;

		-5	we do not have significant obligations for future performance to directly bring about the resale of our product; and

		-6	we have a reasonable basis to estimate returns.
	Our gross revenue is reduced by our gross-to-net (“GTN”) estimates each period, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if these estimates are not reasonably determinable at the time of sale. These estimates are based upon information received from external sources (e.g., written and oral information obtained from our wholesalers with respect to their period-end inventory levels and their sales to end-users during the period), in combination with management’s judgments and estimates. Due to the inherent uncertainty of the inputs that these estimates are based upon, the actual amount we incur may be prospectively reported by us as a revenue adjustment in periods after the initial sale is recorded, and could be materially different from our initial estimates.
	Our GTN estimates include the following major categories:
	Product Returns Allowances: Our FUSILEV, MARQIBO, and BELEODAQ customers are permitted to return purchased products for a refund or credit beginning at its expiration date and within six months thereafter. Returned product is generally not resold by us. Returns for expiry of ZEVALIN and FOLOTYN are not contractually or customarily allowed. We estimate potential returns based on historical rates of return.
	Government Chargebacks: Our products are subject to pricing limits under federal government programs. Qualifying entities (i.e., end-users) purchase products from our wholesalers at their qualifying discounted price. The chargeback amount we incur represents the difference between our original sales price to the wholesaler, and the end-user’s applicable discounted purchase price. There may be significant lag time between our original sale to the wholesaler and our receipt of the corresponding government chargeback claims from our wholesalers.
	Prompt Pay Discounts: Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage.
	Commercial Rebates: Rebates are estimated based on our customer’s actual purchase level during the quarterly or annual rebate purchase period, and the corresponding contractual rebate tier we expect each customer to achieve.
	Medicaid Rebates: Our products are subject to state government-managed Medicaid programs, whereby rebates for purchases are issued to participating state governments. These rebates arise when the patient treated with our products is covered under Medicaid. Our calculations related to these Medicaid rebate accruals require us to estimate end-user and patient mix to determine which of our sales will likely be subject to these rebates. There is a significant time lag in us receiving these rebate notices (generally several months after our sale is made). Our estimates are based on our historical claims from participating state governments, as supplemented by management’s judgment.

	Distribution and Data Fees: Distribution, data, and group purchasing organization (GPO) administrative fees are paid to authorized wholesalers of our products (except for U.S. sales of ZEVALIN) for various services, including: contract administration, inventory management, end-user sales data, and product returns processing. These fees are based on a contractually determined percentage of applicable sales.
	(b) License Fees: We recognize revenue for our licensing of intellectual property to third parties (i.e., out-licenses), based on the contractual terms of each agreement and our application of pertinent GAAP. This revenue may be associated with upfront license fees, milestone payments from our licensees’ sales or regulatory achievements, and royalties from our licensees’ sales in applicable territories.
	(c) Service Revenue: We receive fees under certain arrangements for research and development activities, clinical trial management, and supply chain services. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, regulatory approval events, or completion of product delivery in our capacity as an agent in such arrangement. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.
	(d) New Revenue Recognition Standard: ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), was issued in May 2014 for our mandatory adoption beginning January 1, 2017 (no early adoption is permitted under this new revenue recognition standard). ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, the guidance provides that an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation. We continue to evaluate the impact of ASU 2014-09 to our current revenue recognition models for product sales, license fees, and service revenue, as described above.
	(ii) Cash and Cash Equivalents
	Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the original purchase date.
	(iii) Marketable Securities
	Our marketable securities consist of our holdings in mutual funds and bank certificates of deposit. Since we classify these securities as “available-for-sale” under applicable GAAP, any unrealized gains or losses from their change in value is reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive (Loss) Income. Realized gains and losses on available-for-sale securities are included in “other (expense) income, net” on the accompanying Consolidated Statements of Operations.
	(iv) Accounts Receivable
	Our accounts receivables are derived from our product sales, license fees, and service revenue, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
	(v) Inventories
	We value inventory at the lower of (i) the actual cost to purchase or manufacture it, or (ii) its current market value. Inventory cost is determined on the first-in, first-out method (FIFO). We regularly review our inventory quantities in process of manufacture and on hand, and when appropriate, record a provision for obsolete and excess inventory, which takes into account our sales forecasts by product and corresponding expiry dates. Direct and indirect manufacturing costs related to the production of inventory prior to its FDA approval are expensed through “research and development,” rather than being capitalized to inventory cost.
	(vi) Property and Equipment
	Our property and equipment is presented at historical cost, less accumulated depreciation. It is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.
	(vii) Goodwill and Intangible Assets
	Our goodwill represents the excess of our business acquisition cost over the estimated fair value of the net assets acquired in the corresponding transaction. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is evaluated for impairment on an annual basis (as of each October 1st), unless we identify impairment indicators that would require earlier testing. We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s (whether indefinite or definite-lived) carrying amount may not be recoverable. Such circumstances could include, but are not limited to, the following:

		(a)	a significant decrease in the market value of an asset;

		(b)	a significant adverse change in the extent or manner in which an asset is used; or

		(c)	an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.
	Intangible assets with finite useful lives are amortized over their respective patent term or orphan drug exclusivity period on a straight-line basis. We review these assets for potential impairment if/when facts or circumstances suggest that the carrying value of these assets may not be recoverable.
	(viii) Stock-Based Compensation
	Stock-based compensation expense for equity awards granted to our employees and members of our board of directors is recognized on a straight-line basis over the award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, which estimates those shares expected to be forfeited prior to vesting. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) which carry service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) which carry combined market conditions and service conditions for vesting.

	Calculating and recording stock-based compensation expense requires the use of highly subjective assumptions, including the pre-vesting forfeiture rate, expected dividend payments, expected term of the awards, stock price volatility, and risk-free interest rates. We estimate the expected term of options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant, based on historical volatility of our common stock for a look-back period that corresponds with the expected term. We do not expect to declare any cash dividends in the foreseeable future. We estimate the risk-free interest rate based upon the U.S. Treasury yields in effect at award grant, for a period equaling the stock options’ expected term.
	(ix) Foreign Currency Translation
	We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the reported balance sheet date. Revenues and expenses are translated using average exchange rates during the reported period. Unrealized gains and losses from the translation of our subsidiaries’ financial statements (that are initially denominated in its foreign functional currency) are included as a separate component of “accumulated other comprehensive loss” in the Consolidated Balance Sheets.
	We record foreign currency transactions, when initially denominated in a currency other than the respective functional currency of our subsidiary, at the prevailing exchange rate on the date of the transaction. Resulting in unrealized and realized gains and losses, including those associated with intercompany loans with our foreign subsidiaries to support their operations, and whose functional currency is not the U.S. dollar, are included in “Other (expense) income, net” within the Consolidated Statements of Operations. This presentation is based on our expectation and intent that these intercompany transactions will be settled in the foreseeable future.
	(x) Basic and Diluted Net (Loss) Income per Share
	We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
	(xi) Income Taxes
	Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.
	We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made.
	In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “(Provision) benefit for income taxes” within the Consolidated Statements of Operations and Comprehensive (Loss) Income in the period the notice was received.
	(xii) Research and Development Costs
	Research and development costs are expensed as incurred, or as certain milestone payments become due (generally triggered by contractual clinical or regulatory events).

(xiii) Fair Value Measurements
We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.
Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
“Cash and cash equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of mutual funds that are valued utilizing Level 2 inputs. “Other assets” include our stockholdings of CASI that are valued utilizing Level 1 inputs.
The fair value of our “drug development liability” within our accompanying Consolidated Balance Sheets was estimated using the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.
“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with our business combinations. See Note 10(a) for a discussion of contingent value rights granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

Balance_Sheet_Account_Detail

Balance Sheet Account Detail	12 Months Ended
Balance Sheet Account Detail	Dec. 31, 2014
Text Block [Abstract]
Balance Sheet Account Detail	3. BALANCE SHEET ACCOUNT DETAIL
	The composition of selected financial statement captions that comprise the accompanying Consolidated Balance Sheets are summarized below:
	(a) Cash and Cash Equivalents and Marketable Securities
	As of December 31, 2014 and December 31, 2013, our holdings included in “cash and cash equivalents” and “marketable securities” were at major financial institutions.
	Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, and limited investments in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation (FDIC) and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks on our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

	The carrying amount of our equity securities, money market funds, bank certificate of deposits (“Bank CDs”), and mutual funds approximates their fair value (utilizing Level 1 or Level 2 inputs – see Note 9) because of our ability to immediately convert these instruments into cash with minimal expected change in value.
	The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:


			Cost				Gross				Gross			Estimated			Cash and			Marketable Securities
							Unrealized				Unrealized			fair Value			equivalents			Marketable Securities
							Gains				Losses									Current			Long
																				Current			Term
	December 31, 2014
	Bank deposits		$	62,997			$	—			$	—		$	62,997		$	62,997		$	—		$	—
	Money market funds			66,945				—				—			66,945			66,945			—			—
	Bank CDs			244				—				—			244			—			244			—
	Mutual funds			3,062				—				—			3,062			—			3,062			—

	Total cash and equivalents and marketable securities		$	133,248			$	—			$	—		$	133,248		$	129,942		$	3,306		$	—

	December 31, 2013
	Bank deposits		$	55,911			$	—			$	—		$	55,911		$	55,911		$	—		$	—
	Money market funds			100,395											100,395			100,395
	Bank CDs			410				—				—			410			—			410			—
	Mutual funds			3,061				—				—			3,061			—			3,061			—

	Total cash and equivalents and marketable securities		$	159,777			$	—			$	—		$	159,777		$	156,306		$	3,471		$	—

	As of December 31, 2014, none of these securities had been in a continuous unrealized loss position longer than one year.

	(b) Property and Equipment
	“Property and equipment, net of accumulated depreciation” consist of the following:


			December 31,
			2014				2013
	Computers and software		$	3,616			$	5,154
	Lab and media equipment			643				1,063
	Office furniture and equipment			344				1,575
	Leasehold improvements			2,847				2,813

	Property and equipment, at cost			7,450				10,605
	(Less): accumulated depreciation and amortization			(6,045	)			(9,070	)

	Property and equipment, net		$	1,405			$	1,535

	Depreciation expense (included within “Operating costs and expenses” in the accompanying Consolidated Statements of Operations) for the years ended December 31, 2014, 2013, and 2012 was $1.1 million, $1.2 million, and $1.2 million, respectively. During the year ended December 31, 2014, we corrected our property and equipment balances to remove assets which were determined to no longer be in use (property and equipment at cost of $4.2 million, less accumulated depreciation of $4.0 million).

	(c) Inventories
	“Inventories” consist of the following:


			December 31,
			2014				2013
	Raw materials		$	1,507			$	1,794
	Work in process			3,979				3,312
	Finished goods			3,714				8,413

	Inventories		$	9,200			$	13,519

	(d) Accounts receivables, net of allowance for doubtful accounts
	“Accounts receivables, net of allowance for doubtful accounts” consists of trade receivables from our customers. We are exposed to credit risk associated with trade receivables that result from these product sales. We do not require collateral or deposits from our customers due to our assessment of their creditworthiness and our long-standing relationship with them. We maintain reserves for potential bad debt, though credit losses have historically been nominal and within management’s expectations. A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2014 and 2013 are as follows:


		Year Ended December 31,
		2014								2013
Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)		$	36,154				51.1	%		$	18,655			37.7	%
McKesson Corporation and its affiliates			22,534				31.9	%			15,191			30.7	%
Integrated Commercialization Solutions, Inc. (“ICS”)			8,432				11.9	%			*			—	%
Cardinal Health, Inc. and its affiliates			*				—	%			5,097			10.3	%
All Other Customers			3,638				5.1	%			10,540			21.3	%

Total Accounts Receivables, net		$	70,758				100	%		$	49,483			100	%


*	Less than 10%

(e) Other receivables
“Other receivables” consist of (i) amounts we expect to be refunded from taxing authorities for our income taxes paid, relating to fiscal year 2012, and (ii) amounts we expect to be contractually reimbursed from third-parties for certain of our incurred expenses.


		December 31,				December 31,
		2014				2013
Income tax receivable		$	1,387			$	7,539
Receivables from third parties for certain of our incurred expenses			4,102				—

		$	5,489			$	7,539

(f) Intangible Assets and Goodwill
“Intangible assets, net of accumulated amortization” consist of the following:


						December 31, 2014
		Historical				Accumulated				Foreign			Impairment			Net Amount			Full			Remaining
		Cost				Amortization				Currency									Amortization			Amortization
										Translation									Period			Period
																			(months)			(months)
MARQIBO IPR&D (NHL and further ALL indications)		$	17,600			$	—			$	—		$	—		$	17,600			n/a			n/a
C-E MELPHALAN IPR&D			7,700				—				—			—			7,700			n/a			n/a
BELEODAQ distribution rights			25,000				(937	)			—			—			24,063			160			154
MARQIBO distribution rights			26,900				(4,225	)			—			—			22,675			81			63
FOLOTYN distribution rights			118,400				(20,030	)			—			—			98,370			152			125
ZEVALIN distribution rights – U.S.			41,900				(27,134	)			—			—			14,766			122			48
ZEVALIN distribution rights – Ex-U.S.			23,490				(7,402	)			(2,162	)		—			13,926			95			62
FUSILEV distribution rights			16,778				(6,270	)			—			—			10,508			84			40
FOLOTYN out-license*			27,900				(6,385	)			—			(1,023	)		20,492			110			91

Total intangible assets		$	305,668			$	(72,383	)		$	(2,162	)	$	(1,023	)	$	230,100


*	On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., FOLOTYN rights). We determined that an impairment of the FOLOTYN out-license rights to Mundipharma of $1.0 million resulted from this amendment.

Our annual impairment evaluation (as of October 1st) of our indefinite-lived intangible assets was completed by our management in 2014, with no resulting impairment. The assets under review included MARQIBO IPR&D and C-E MELPHALAN IPR&D, which we carry on our accompanying Consolidated Balance Sheet as of December 31, 2014, at $17.6 million and $7.7 million, respectively.


						December 31, 2013
		Historical				Accumulated				Foreign			Impairment			Net Amount
		Cost				Amortization				Currency
										Translation
MARQIBO IPR&D (NHL and further ALL indications)		$	17,600			$	—			$	—		$	—		$	17,600
C-E MELPHALAN IPR&D			7,700				—				—			—			7,700
MARQIBO distribution rights			26,900				(1,107	)			—			—			25,793
ZEVALIN distribution rights – U.S.			41,900				(23,455	)			—			—			18,445
ZEVALIN distribution rights – Ex-U.S.			23,490				(5,343	)			682			—			18,829
FUSILEV distribution rights			16,778				(4,821	)			—			—			11,957
FOLOTYN out-license			27,900				(3,662	)			—			(1,023	)		23,215
FOLOTYN distribution rights			118,400				(10,587	)			—			—			107,813

Total intangible assets		$	280,668			$	(48,975	)		$	682		$	(1,023	)	$	231,352


Intangible asset amortization expense recognized in 2014, 2013, and 2012 was $24.3 million, $21.2 million, and $8.8 million, respectively. Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:


Years Ending December 31
2015			25,937
2016			25,937
2017			25,937
2018			25,937
2019			23,332
2020 and thereafter			77,720

		$	204,800

“Goodwill” is comprised of the following (by source):


		December 31,				December 31,
		2014				2013
Acquisition of Talon		$	10,526			$	10,526
Acquisition of ZEVALIN Ex-U.S. distribution rights			2,525				2,525
Acquisition of Allos			5,346				5,346
Foreign currency exchange translation effects			(202	)			104

		$	18,195			$	18,501

(g) Other assets
“Other assets” are comprised of the following:


		December 31,				December 31,
		2014				2013
Equity securities (see Note 11)		$	8,501			$	3,593
Supplies			234				190
2018 Convertible Notes issuance costs			2,171				3,432
Executive officer life insurance – cash surrender value			6,958				5,362

		$	17,864			$	12,577

(h) Accounts payable and other accrued obligations
Accounts payable and other accrued obligations are comprised of the following:


		December 31,
		2014				2013
Trade payables		$	8,994			$	12,796
Accrued research and development expenses			5,423				6,433
Accrued selling, general and administrative expenses			10,154				8,870
Accrued rebates			41,782				28,893
Accrued product royalty			5,182				9,498
Allowance for returns			1,135				2,900
Accrued data and distribution fees			3,952				2,430
Accrued GPO administrative fees			3,222				2,327
Inventory management fee			1,110				616
Allowance for chargebacks			4,040				5,074

		$	84,994			$	79,837


Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:


Description		Rebates and				Data and				Returns
		Chargebacks				Distribution,
						GPO Fees, and
						Inventory
						Management
						Fees
Balance as of December 31, 2012		$	26,176			$	14,149			$	5,056
Add: provisions (recovery)			63,609				19,067				(2,034	)
(Less): credits or actual allowances			(55,818	)			(27,843	)			(122	)

Balance as of December 31, 2013			33,967				5,373				2,900
Add: provisions (recovery)			76,636				21,330				(78	)
(Less): credits or actual allowances			(64,781	)			(18,419	)			(1,687	)

Balance as of December 31, 2014		$	45,822			$	8,284			$	1,135
(i) Other long-term liabilities
Other long-term liabilities are comprised of the following:


		December 31,
		2014				2013
Accrued executive deferred compensation		$	4,694			$	3,949
Deferred rent (non-current portion)			364				366
Business acquisition liability			300				298
Other tax liabilities			730				1,352

		$	6,088			$	5,965

(j) Accumulated other comprehensive (loss) income
“Accumulated other comprehensive (loss) income” (a component of stockholders’ equity) includes, among other items, unrealized gains and losses from available-for-sale securities (“AFS”). When AFS securities are sold, and the resulting gain or loss is realized, any corresponding unrealized gain or loss amounts previously included within accumulated other comprehensive income is eliminated. During 2014, we sold certain stock holdings that had been classified as an AFS. As a result, $2.2 million was recognized as a realized gain through “other (expense) income, net” on our Consolidated Statement of Operations for the year ended December 31, 2014.

GrosstoNet_Product_Sales

Gross-to-Net Product Sales	12 Months Ended
Gross-to-Net Product Sales	Dec. 31, 2014
Text Block [Abstract]
Gross-to-Net Product Sales	4. GROSS-TO-NET PRODUCT SALES
	The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:


		2014			2013			2012
	Gross product sales	$	284,685		$	224,301		$	383,817
	Rebates and chargebacks		(76,636	)		(63,610	)		(91,059	)
	Data, distribution and GPO administration fees		(21,330	)		(19,067	)		(32,793	)
	Prompt pay discount		(260	)		(183	)		(4,814	)
	Product returns allowance		78			2,034			(159	)

	Product sales, net	$	186,537		$	143,475		$	254,992

Net_Product_Sales_by_Geographi

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers	5. NET PRODUCT SALES BY GEOGRAPHIC REGION, PRODUCT LINE, AND GROSS PRODUCT SALES BY SIGNIFICANT CUSTOMERS
	The below table presents our net product sales by geography for the years ended December 31, 2014, 2013, and 2012:
	Net Product Sales by Geographic Region


			Year Ended December 31,
			2014				2013				2012
	United States		$	177,979	95.4	%	$	133,462	93	%	$	245,697	96.4	%

	International:
	Europe (ZEVALIN only)			3,357	1.8	%		3,953	2.8	%		3,113	1.2	%
	Asia Pacific (ZEVALIN only)			5,201	2.8	%		6,060	4.2	%		6,182	2.4	%

	Total International			8,558	4.6	%		10,013	7	%		9,295	3.6	%

	Net product sales		$	186,537	100	%	$	143,475	100	%	$	254,992	100	%

	Net Sales by Product
	The below table presents our net product sales by product line for the years ended December 31, 2014, 2013, and 2012:


			Year Ended December 31,
			2014				2013				2012
	FUSILEV		$	105,608	56.6	%	$	68,397	47.7	%	$	204,253	80.1	%
	FOLOTYN			47,556	25.5	%		44,370	30.9	%		20,412	8	%
	ZEVALIN			22,169	11.9	%		29,393	20.5	%		30,327	11.9	%
	MARQIBO			6,328	3.4	%		1,315	0.9	%		—	—	%
	BELEODAQ			4,876	2.6	%		—	—	%		—	—	%

	Net product sales		$	186,537	100	%	$	143,475	100	%	$	254,992	100	%


	Gross Product Sales by Customer
	The below table presents the customers that represent 10% or more of our gross product sales in 2014, 2013, and 2012:


			Year Ended December 31,
			2014				2013				2012
	Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)		$	115,079	40	%	$	79,497	35.4	%	$	101,712	26.5	%
	McKesson Corporation and its affiliates			93,656	32.1	%		44,350	19.8	%		89,046	23.2	%
	Integrated Commercialization Solutions, Inc. (“ICS”)			*	—	%		35,548	15.8	%		74,461	19.4	%
	Cardinal Health, Inc. and its affiliates			*	—	%		*	—	%		60,259	15.7	%
	All Other Customers			75,950	27.9	%		64,906	29	%		58,339	15.2	%

	Gross product sales		$	284,685	100	%	$	224,301	100	%	$	383,817	100	%


	*	Less than 10%

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	6. STOCK-BASED COMPENSATION
	2009 Stock Incentive Plan
	We have one active stockholder-approved stock-based compensation plan, the 2009 Incentive Award Plan (the “2009 Plan”), which replaced our former stockholder-approved plans. We may grant incentive stock options, non-qualified options, restricted stock awards, and stock appreciation rights under the 2009 Plan.
	The maximum number of our common stock available for issuance under the 2009 Plan at inception was 10 million shares. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the 2009 Plan automatically increases by the greater of (i) 2.5 million shares or (ii) a number of shares such that the total number of shares of common stock available for issuance under the 2009 Plan shall equal 30% of the then number of shares of common stock issued and outstanding. As of December 31, 2014, 9.5 million shares were available for grant. It is our policy that before stock is issued through the exercise of stock options, we must first receive all required cash payment for such shares (whether through an upfront cash exercise or net-settlement exercise).
	Stock-based awards are governed by agreements between us and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2009 Plan at an exercise price of not less than 100% of the closing fair market value of our common stock on the respective date of grant. The grant date is generally the date the award is approved by the Compensation Committee of the Board of Directors, though for aggregate awards of 50,000 or less in each quarter, the grant date is the date the award is approved by our Chief Executive Officer.
	Stock-based awards generally vest 25% on the first anniversary of the date of grant, or for new hires, the first anniversary of their initial date of employment. Awards generally vest monthly thereafter on a straight-line basis over three years. Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 90 days from the last date of employment. In the event of an optionee’s death, disability, or retirement, the exercise period is 365 days from the last date of employment.

	Employee Stock Purchase Plan
	Under the terms of our 2009 Employee Stock Purchase Plan (the “ESPP”), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of our common stock on the first or last day of the offering period (whichever is less), minus a 15% discount. We use the Black-Scholes option-pricing model, in combination with the discounted employee price, in determining the value of ESPP expense to be recognized during each offering period. A participant may purchase a maximum of 50,000 shares of common stock during a six-month offering period, not to exceed $25,000 worth of stock on the offering date during each plan year.
	A total of 4.4 million shares of common stock are authorized for issuance under the ESPP. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the ESPP shall automatically increase by an amount equal to the lesser of (i) one million shares or (ii) an amount determined by the ESPP administrator. However, in no event shall the number of shares of common stock available for future sale under the ESPP exceed 10 million shares, subject to capitalization adjustments occurring due to dividends, splits, dissolution, liquidation, mergers, or changes in control.
	Stock-Based Compensation Expense Summary
	We classify our stock-based compensation expense (inclusive of our 2009 Plan, ESPP, and 401(k) matching) in the accompanying Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within operating expenses for years ended December 31, 2014, 2013, and 2012 was as follows:


			Year Ended December 31,
			2014				2013			2012
	Selling, general and administrative		$	10,053			$	10,762		$	13,041
	Research and development			1,756				2,017			1,843

	Total		$	11,809			$	12,779		$	14,884

	Employee stock-based compensation expense for the years ended December 31, 2014, 2013, and 2012 was recognized (reduced for estimated forfeitures) on a straight-line basis over the vesting period. Forfeitures are estimated at the time of grant and prospectively revised if actual forfeitures differ from those estimates. We estimate forfeitures of stock options using the historical exercise behavior of our employees. For purposes of this estimate, we have applied an estimated forfeiture rate of 8%, 8%, and 5% for the years ended December 31, 2014, 2013, and 2012.
	Valuation Assumptions – Restricted Stock and Stock Options
	The grant-date fair value per share for restricted stock awards was based upon the closing market price of our common stock on the award grant-date.

	The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:


			Year Ended December 31,
			2014		2013		2012
	Expected option life (in years) (a)		4.95		4.95		4.5
	Risk-free interest rate (b)		0.58% - 1.52%		0.35% - 0.78%		0.34% - 0.51%
	Volatility (c)		48.9% - 62.1%		58.3% -71.5%		64.2% - 73.6%
	Dividend yield (d)		0%		0%		0%
	Weighted-average grant-date fair value per stock option		$3.49		$4.66		$6.20

	(a)	Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
	(b)	Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
	(c)	Measured using our historical stock price for a period equal to stock options’ expected term.
	(d)	We do not expect to declare any cash dividends in the foreseeable future.
	Stock Option Activity
	Stock option activity during the years ended December 31, 2014, 2013, and 2012 is as follows:


			Number of				Weighted-			Weighted-			Aggregate
			Shares				Average			Average			Intrinsic
							Exercise			Remaining			Value
							Price/Share			Contractual
										Term (Years)
	Outstanding — December 31, 2011			10,185,521			$	5.46
	Granted			1,821,915				11.57
	Exercised			(1,287,430	)			4.52					$	11,500	(1)
	Forfeited			(316,825	)			7.93
	Expired			(3,916	)			7.69

	Outstanding — December 31, 2012			10,399,265				6.57
	Granted			2,041,300				8.92
	Exercised			(825,884	)			4.4					$	3,435	(1)
	Forfeited			(202,882	)			8.22
	Expired			(82,581	)			8.91

	Outstanding — December 31, 2013			11,329,218				7.1
	Granted			2,576,292				7.6
	Exercised			(485,260	)			4.77					$	1,629	(1)
Forfeited			(557,109	)			9.65
Expired			(214,039	)			10.7

Outstanding — December 31, 2014			12,649,102			$	7.12			6.61		$	11,679	(2)

Vested (exercisable) — December 31, 2014			9,134,760			$	6.62			5.66		$	11,678	(2)

Unvested (unexercisable) — December 31, 2014			3,514,342			$	8.42			9.07		$	766	(2)


-1	Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
-2	Represents the total difference between our closing stock price on the last trading day of 2014 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2014. The amount of intrinsic value will change based on the fair market value of our stock.
The following table summarizes information with respect to stock option grants as of December 31, 2014:


		Outstanding										Exercisable
Exercise Price		Granted Stock				Weighted-			Weighted-			Granted				Weighted-
		Options				Average			Average			Stock				Average
		Outstanding				Remaining			Exercise			Options				Exercise
						Contractual			Price			Exercisable				Price
						Life (Years)
$0.92 – 3.15			1,135,594				3.47		$	2.19			1,135,594			$	2.19
$3.16 – 4.95			1,673,317				4.89			4.24			1,673,317				4.24
$4.96 – 6.9			2,708,119				4.42			6.27			2,701,899				6.27
$6.91 – 8.99			4,539,130				8.41			7.86			1,983,129				8.09
$9.00 – 16.32			2,592,942				8.21			10.75			1,640,821				10.94

			12,649,102				6.61		$	7.12			9,134,760			$	6.62

As of December 31, 2014, there was unrecognized compensation expense of $11.4 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.54 years.

Restricted Stock Award Activity
A summary of restricted stock award activity is as follows:


		Number of				Weighted Average
		Restricted Stock				Fair Value per
		Awards				Share at Grant
						Date
Unvested as of December 31, 2011			952,525			$	10.11
Granted			586,639				11.76
Vested			(472,160	)			10.26
Forfeited			(32,400	)			9.57

Unvested — December 31, 2012			1,034,604				11
Granted			523,800				8.74
Vested			(501,660	)			9.72
Forfeited			(49,625	)			10.6

Unvested — December 31, 2013			1,007,119				10.09
Granted			581,194				7.52
Vested			(578,985	)			10.24
Forfeited			(185,111	)			9.88

Unvested — December 31, 2014			824,217			$	8.22



		2014				2013			2012
Restricted stock expense		$	3,830			$	4,202		$	6,500
As of December 31, 2014, there was approximately $4.9 million of unrecorded expense related to issued restricted stock that will be recognized over an estimated weighted average period of 2.8 years. These unvested shares are included in our issued and outstanding common stock as of December 31, 2014.
401(k) Plan – Stock Matching Contribution
We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employees’ annual 401(k) contributions, as summarized below:


		2014				2013			2012
Shares of common stock issued			133,734				99,359			56,254
Match contribution value*		$	1,028			$	860		$	691

*	Represents our stock price on the date of the common stock issuance multiplied by the number of shares of common stock issued.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	7. STOCKHOLDERS’ EQUITY
	Authorized Stock
	On December 13, 2010, we filed the Certificate of Designation of Rights, Preferences and Privileges of Series B Junior Participating Preferred Stock with the Delaware Secretary of State which authorized 1.5 million shares to be designated as Series B Junior Participating Preferred Stock. On June 13, 2011, our stockholders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of our common stock from 100 million shares to 175 million shares. The amendment was filed with the Delaware Secretary of State on June 24, 2011. As of December 31, 2014, we also had five million shares of preferred stock authorized, of which 1.5 million shares were designated as Series B Junior Participating Preferred Stock and 2,000 shares were designated as Series E Convertible Voting Preferred Stock.

	Stockholder Rights Agreement
	On November 29, 2010, our Board of Directors approved a replacement rights agreement, effective December 13, 2010, that replaced the stockholder rights agreement which was originally adopted in 2000. This replacement rights agreement will extend until December 13, 2020. A stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive tactics that might be used in an attempt to gain control of our company. A stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire our company to first negotiate with our Board of Directors.
	Under the terms of the new Stockholder Rights Agreement, the rights become exercisable upon the earlier of 10 days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or 10 business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our company, even if doing so would potentially benefit our stockholders.
	We currently have no stockholders who own 15% or more of the outstanding shares of our common stock. Five days after the rights become exercisable, each right, other than rights held by the person or group of affiliated persons whose acquisition of more than 15% of our outstanding common stock caused the rights to become exercisable, will entitle its holder to buy, in lieu of shares of Series B Preferred Stock, a number of shares of our common stock having a market value of twice the exercise price of the rights. After the rights become exercisable, if we are a party to certain merger or business combination transactions or transfers 50% or more of our assets or earnings power (as defined in the Stockholder Rights Agreement), each right will entitle its holder to buy a number of shares of common stock of the acquiring or surviving entity having a market value of twice the exercise price of the right.
	Series E Preferred Stock
	In September 2003, we received gross cash proceeds of $20 million in exchange for the issuance of 2,000 shares of our Series E Convertible Voting Preferred Stock, convertible into four million shares of common stock. As of December 31, 2014 and 2013, 20 shares of Series E Preferred Stock were outstanding. No dividends are payable on the Series E Preferred Stock. Pursuant to certain provisions of the Certificate of Designation, Rights and Preferences of the Series E Preferred Stock, we have the option to redeem all of the unconverted Series E Preferred Stock outstanding at the end of a 20-day trading period if, among other things, in that period our common stock trades above $12.00 per share.
	In the event we are the subject of any voluntary or involuntary liquidation, dissolution or winding up, before any distribution of our assets shall be made to the common stockholders, the holders of the Series E Preferred Stock shall be entitled to receive a liquidation preference in an amount equal to 120% of the stated value per share plus any declared and unpaid dividends thereon.
	Common Stock Issuable
	As of December 31, 2014, 24.9 million shares of our common stock were issuable upon conversion, or exercise of rights granted (regardless of whether in or out-of-the-money), as summarized below:


	Conversion of Series E Preferred Stock		40,000
	2018 Convertible Notes		11,400,000
	Exercise of issued employee stock options		12,649,102
	Exercise of issued warrants		445,000
	Management incentive plan restricted stock units		346,500

	Total common shares		24,880,602


	Warrant Activity
	We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents or consultants. Our outstanding warrants expire on varying dates through December 2015. A summary of warrant activity is as follows:


		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding — December 31, 2011		445,000		$	5.04
	Exercised		(50,000	)		1.79

	Outstanding — December 31, 2012		395,000		$	5.45
	Granted		50,000			7.51

	Outstanding — December 31, 2013		445,000		$	6.39
	Granted		—			—

	Outstanding — December 31, 2014		445,000		$	6.39

	Exercisable — December 31, 2014		445,000		$	6.39

Net_Loss_Income_Per_Share

Net (Loss) Income Per Share	12 Months Ended
Net (Loss) Income Per Share	Dec. 31, 2014
Earnings Per Share [Abstract]
Net (Loss) Income Per Share	8. NET (LOSS) INCOME PER SHARE
	Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2014, 2013, and 2012:


		Year Ended December 31,
		2014			2013			2012
	Net (loss) income	$	(45,719	)	$	(62,134	)	$	94,201
	Weighted average shares—basic		64,708,163			60,729,128			58,588,916
	Net (loss) income per share—basic	$	(0.71	)	$	(1.02	)	$	1.61
	Weighted average shares—diluted		64,708,163			60,729,128			64,637,256
	Net (loss) income per share—diluted	$	(0.71	)	$	(1.02	)	$	1.46

	The following summarizes the amounts used in computing basic and diluted net income per share, for the year ended 2012:


		Net Income			Weighted-			Net
		(numerator)			Average			Income
					Shares			Per Share
					Outstanding
					(Denominator)
	Year Ended December 31, 2012
	Basic net income per share:	$	94,201			58,588,916		$	1.61

	Diluted net income per share:
	Dilutive preferred shares					40,000
	Dilutive common stock options					4,749,299
	Incremental common stock assumed issued on exercise of in-the-money warrants					224,437
	Unvested restrictive stock awards					1,034,604

	Diluted net income per share	$	94,201			64,637,256		$	1.46

	Certain of our outstanding securities were excluded from the above calculation of net loss per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net loss per share:


		Year Ended December 31,
		2014			2013			2012
	2018 Convertible Notes		11,401,284			343,600			—
	Common stock options		2,173,916			2,934,625			—
	Restricted stock awards		824,217			1,007,119			—
	Common stock warrants		120,702			160,816			—
	Preferred stock		40,000			40,000			—

	Total		14,560,119			4,486,160			—

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. FAIR VALUE MEASUREMENTS
	The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories:


			December 31, 2014
			Fair Value Measurements
			Level 1			Level 2		Level 3		Total
	Assets:
	Bank CDs		$	—		$	244	$	—	$	244
	Money market currency funds			—			66,945		—		66,945
	Equity securities			9,959			—		—		9,959
	Mutual funds			—			3,062		—		3,062
	Deferred compensation investments, including life insurance cash surrender value			—			6,958		—		6,958

			$	9,959		$	77,209	$	—	$	87,168

	Liabilities:
	Deferred executive compensation liability			—			4,694		—		4,694
	Deferred development costs			—			—		15,785		15,785
	Ligand Contingent Consideration			—			—		4,901		4,901
	Talon CVR			—			—		2,379		2,379
	Corixa Liability			—			—		62		62

			$	—		$	4,694	$	23,127	$	27,821



			December 31, 2013
			Fair Value Measurements
			Level 1			Level 2		Level 3		Total
	Assets:
	Bank CDs		$	—		$	410	$	—	$	410
	Money market currency funds						100,395		—		100,395
	Mutual funds			—			3,061		—		3,061
	Deferred compensation investments, including life insurance cash surrender value			—			5,361		—		5,361
	Equity securities			3,593			—		—		3,593

			$	3,593		$	109,227	$	—	$	112,820

	Liabilities:
	Deferred executive compensation liability			—			3,949		—		3,949
	Deferred development costs			—			—		17,742		17,742
	Ligand Contingent Consideration			—			—		4,000		4,000
	Talon CVR			—			—		4,329		4,329

			$	—		$	3,949	$	26,071	$	30,020

	We did not have any transfers between Levels 1 and 2 for all periods presented. The following presents a roll forward of our liabilities for which we utilize Level 3 inputs in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “drug development liability, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.
	Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration liabilities, approximate their related fair values due to their short-term nature.


			Fair Value Measurements of
			Unobservable Inputs
			(*Level 3*)
	Balance at December 31, 2012		$	14,520
	Transfers in (out)			—
	Deferred development costs			5,509
	Deferred payment contingency			(2,287	)
	Ligand Contingent Consideration			4,000
	Talon CVR			4,329

	Balance at December 31, 2013		$	26,071
	Transfers in (out)			—
	Deferred development costs (see Note 14)			(1,957	)
Deferred payment contingency (see Note 14)			—
Ligand Contingent Consideration (see Note 10(b))			901
Talon CVR (see Note 10(a))			(1,950	)
Corixa Liability (see Note 15(b)(i))			62

Balance at December 31, 2014		$	23,127

Business_Combinations_and_Cont

Business Combinations and Contingent Consideration	12 Months Ended
Business Combinations and Contingent Consideration	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations and Contingent Consideration	10. BUSINESS COMBINATIONS AND CONTINGENT CONSIDERATION
	(a) Acquisition of Talon Therapeutics, Inc.
	Talon Acquisition Overview
	On July 17, 2013, we purchased all of the outstanding shares of common stock of Talon Therapeutics, Inc. (“Talon”). Through the acquisition of Talon, we gained worldwide rights to MARQIBO. The Talon purchase consideration comprised of (i) an aggregate upfront cash amount of $11.3 million, (ii) issuance of 3.0 million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July 17, 2013), and (iii) the issuance of contingent value rights (“CVR”) initially valued at $6.5 million. The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 2 (xiii)). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:

		•		$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year

		•		$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year

		•		$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year

		•		$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year

		•		$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year

		•		$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion
	Talon CVR Fair Value as of December 31, 2014 and December 31, 2013
	The CVR fair value will continue to be evaluated on a quarterly basis. Current and future changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations, and the CVR is presented at each reporting period within “acquisition-related contingent obligations” within long-term liabilities on the accompanying Consolidated Balance Sheets .


			Fair Value
			of Talon
			CVR
	December 31, 2013		$	4,329
	Fair value adjustment for the year ended December 31, 2014			(1,950	)

	December 31, 2014		$	2,379


	Fair Value Estimate of Assets Acquired and Liabilities Assumed
	Under the purchase method of accounting, the total purchase consideration is allocated to Talon net tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date. The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:


	Cash and equivalents		$	131
	Inventory			611
	Prepaid expenses and other current assets			109
	Property and equipment			30
	Identifiable intangible assets			44,500

	Total assets acquired			45,381

	Accounts payable & accrued liabilities			5,231
	Deferred tax liability			6,576

	Total liabilities assumed			11,807

	Net assets acquired		$	33,574

	Goodwill		$	10,526

	The acquired intangible assets consisted of (i) developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and (ii) MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) and other potential indications, as summarized in the table below:


			Value of			Amortization
			Intangible			Period*
			Assets
			Acquired
	Developed technology —MARQIBO for ALL		$	26,900			81 months
	IPR&D —MARQIBO for NHL and other potential indications			17,600			(1	)

	Total identifiable intangible assets		$	44,500


	*	Recognized on a straight-line basis.
-1	IPR&D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but is periodically tested for impairment.

The fair value of the acquired IPR&D technology assets was estimated using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts.
Goodwill
Goodwill presented above of $10.5 million represents the difference of the Talon business purchase price of $44.1 million minus the net assets acquired of $33.6 million. This goodwill includes benefits that we believe will result from combining the operations of Talon with ours, as well as the know-how associated with the MARQIBO compounds for future product development. In accordance with applicable GAAP, we will not amortize goodwill associated with the Talon acquisition, though it will be subjected to annual impairment testing. This goodwill is not deductible for income tax purposes.
(b) Acquisition of Rights to Captisol-Enabled ® MELPHALAN
Overview of Acquisition of Rights to C-E MELPHALAN
In March 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled®, propylene glycol-free MELPHALAN (“C-E MELPHALAN”) for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma from CyDex Pharmaceuticals, Inc. a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”) for an initial license fee of $3.0 million.
We accounted for this transaction as a business combination, which requires that assets acquired and liabilities assumed be recognized on the balance sheet at their fair values, which involves our estimates of future discounted cash flows as of the transaction date.
We are required to pay Ligand additional amounts up to an aggregate $66.0 million, upon the achievement of certain regulatory milestones and net sales thresholds (“Ligand Contingent Consideration”), and we also assumed full financial responsibility for its ongoing clinical and regulatory development program. We also must pay royalties of 20% on our future net sales of C-E MELPHALAN in all territories.
Consideration Transferred
The acquisition-date fair value of the consideration transferred consisted of the following items:


Cash consideration		$	3,000
Ligand Contingent Consideration			4,700

Total purchase consideration		$	7,700

Fair Value Estimate of Asset Acquired and Liability Assumed
The total purchase consideration is allocated to the acquisition of the net tangible and intangible assets based on their estimated fair values as of the closing date. The allocation of the total purchase price to the net assets acquired is as follows:


IPR&D—C-E MELPHALAN rights		$	7,700
We estimated the fair value of the in-process research and development using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts. The fair value estimate took into account our estimates of future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights, and included estimated cash flows of approximately 10 years and a discount rate of approximately 25%.
The fair value of the contingent consideration liability assumed was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable inputs and are therefore classified as Level 3 inputs, which assumes that FDA approval of C-E MELPHALAN will occur on or about December 31, 2015. Upon receipt of FDA approval, we will be obligated to make a milestone payment of $6.0 million to Ligand.
Ligand Contingent Consideration Fair Value
The Ligand Contingent Consideration fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations.


		Fair Value of
		Ligand
		Contingent
		Consideration
December 31, 2013		$	4,000
Fair value adjustment for year ended December 31, 2014			901

December 31, 2014		$	4,901

(c) Allos Acquisition
We acquired Allos Therapeutics, Inc. (“Allos”) on September 5, 2012, which was accounted for as a business combination. Our total cash consideration for this acquisition was $205.2 million, through which we acquired FOLOTYN distribution rights. We have no contingent consideration obligations as part of this transaction.

OutLicense_of_Marqibo_Zevalin_

Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory	11. OUT-LICENSE OF MARQIBO, ZEVALIN, & C-E MELPHALAN IN CHINA TERRITORY
	Overview of CASI Out-License
	On September 17, 2014, we executed three product out-license agreements with a perpetual term (collectively, the “CASI Out-License”) with CASI Pharmaceuticals, Inc. (“CASI”), a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market. Under the CASI Out-License, we granted CASI the exclusive rights to distribute two of our commercialized oncology drugs, ZEVALIN and MARQIBO, and our Phase 3 drug candidate, C-E MELPHALAN (“CASI Out-Licensed Products”) in greater China (which includes Taiwan, Hong Kong and Macau). In return, we received CASI equity for the rights related to ZEVALIN and C-E MELPHALAN and a secured promissory note for the rights related to MARQIBO. Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues securities.
	CASI will be responsible for the development and commercialization of these three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China. We will provide CASI with future commercial supply of the CASI Out-Licensed Products under typical market terms.

	Proceeds Received
	The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following:


	CASI common stock (a) (5.4 million shares)		$	8,649	(a)
	CASI secured promissory note due March 17, 2016, net of fair value discount (b) ($1.5 million face value and 0.5% annual coupon)			1,310	(b)

	Total consideration received		$	9,959	(c)


		•		Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $8.5 million as of December 31, 2014 within “other assets” (rather than “marketable securities”) on our accompanying Consolidated Balance Sheets. The change in the value of these securities at each reporting period is included in “other comprehensive income (loss), net” on the accompanying Consolidated Statement of Comprehensive Income (Loss).

		•		Present value estimated using the terms of the $1.5 million promissory note, and the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014.

		•		Presented within “deferred revenue” in the accompanying Consolidated Balance Sheets as of December 31, 2014.
	In addition, CASI will be responsible for paying any royalties or milestones that we are obligated to pay to our third-party licensors resulting from the achievement of certain milestones and/or sales of CASI Out-Licensed Products, but only to the extent of the greater China portion of such royalties or milestones.
	Recognition of Proceeds – License Fee Revenue
	The $10.1 million value (undiscounted) of the upfront proceeds that we received from CASI are expected to be recognized in 2015 within “license fees and service revenue” through our Consolidated Statements of Operations. The timing of this revenue recognition will correspond with the pending execution of supply agreements with CASI. The pending supply agreements will allow CASI to procure CASI Out-Licensed Products directly from third parties (at their option), and in such case, will not require our future involvement for their supply.

Revolving_Line_of_Credit

Revolving Line of Credit	12 Months Ended
Revolving Line of Credit	Dec. 31, 2014
Debt Disclosure [Abstract]
Revolving Line of Credit	12. REVOLVING LINE OF CREDIT
	We entered into a credit agreement on September 5, 2012 with Bank of America, N.A, as the administrative agent and Wells Fargo Bank, N.A, as an initial lender (the “Credit Agreement”). The Credit Agreement provided us with a committed $50 million revolving line of credit facility (the “Credit Facility”). The Credit Facility was repaid in full, then immediately terminated, on December 20, 2013 in connection with the sale and issuance of our 2018 Convertible Senior Notes (see Note 13).
	We recognized $1.2 million and $0.5 million within “interest expense” in 2013 and 2012, respectively, for this retired Credit Facility on the accompanying Consolidated Statement of Operations.

Convertible_Senior_Notes

Convertible Senior Notes	12 Months Ended
Convertible Senior Notes	Dec. 31, 2014
Text Block [Abstract]
Convertible Senior Notes	13. CONVERTIBLE SENIOR NOTES
	On December 17, 2013, we entered into an agreement for the sale of $120 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances. The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2014. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option.
	The sale of the 2018 Convertible Notes closed on December 23, 2013 and our net proceeds were $115.4 million, after deducting banker and professional fees of $4.6 million. We used a portion of these net proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to “additional paid-in capital” in our accompanying Consolidated Balance Sheets. The Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reported periods.
	We entered into Note Hedge transactions to reduce the potential dilution to our stockholders and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the “bought call” is equal to the conversion price and conversion rate of the 2018 Convertible Notes, matching the 11.4 million common shares the 2018 Convertible Notes may be converted into. The strike price of our “sold warrant” is $14.03 per share of our common stock, and is also for 11.4 million common shares.
	Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under any of the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of (i) the last reported sale price of our common stock on such trading day and (ii) the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; and (4) at any time prior to our stockholders’ approval to settle the 2018 Convertible Notes in our common shares and/or cash. On and after June 15, 2018, and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes.
	As of December 31, 2014, the 2018 Convertible Notes are eligible to be converted into common stock, based on the above element (4) being met, since our stockholders’ approval of this flexible settlement feature has not yet occurred.
	We initially may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval, we may, at our election, settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock.
	The carrying value of the 2018 Convertible Notes as of December 31, 2014 is summarized as follows:


	Principal amount	$	120,000
	(Less): Unamortized debt discount (amortized through December 2018)		(23,702	)

	December 31, 2014	$	96,298


	As of December 31, 2014, the estimated aggregate fair value of the 2018 Notes is $113.2 million, which is less than its principal amount of $120 million, largely since the conversion feature of the 2018 Notes was, and remains, out-of-the money. This estimated fair value represents a Level 2 measurement (see Note 2(xiii)) based upon its December 31, 2014 quoted bid price in a thinly-traded market.
	The following table sets forth the components of total “interest expense, net” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the years ended December 31, 2014 and 2013:


		Year Ended December 31,
		2014			2013
	Contractual coupon interest expense	$	3,300		$	73
	Amortization of debt issuance costs		599			43
	Accretion of debt discount		4,818			101

	Total	$	8,717		$	217
	Effective interest rate		8.66	%		8.59	%

Mundipharma_Agreement

Mundipharma Agreement	12 Months Ended
Mundipharma Agreement	Dec. 31, 2014
Text Block [Abstract]
Mundipharma Agreement	14. MUNDIPHARMA AGREEMENT
	As the result of our acquisition of Allos Therapeutics, Inc. on September 5, 2012 (through which we obtained distribution rights for FOLOTYN), we assumed its obligations under an active strategic collaboration agreement with a third-party, Mundipharma (the “Mundipharma Collaboration Agreement”). Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the “Mundipharma Territories”).
	On May 29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the “Amended Munipharma Collaboration Agreement”), in order to modify: (i) the scope of the licensed territory, (ii) milestone payments, (iii) royalty rates, and (iv) drug development obligations. In connection with the Amended Munipharma Collaboration Agreement, we received a one-time $7.0 million payment from Mundipharma for certain research and development activities to be performed by us.
	As a result of the Amended Mundipharma Collaboration Agreement, (a) Europe and Turkey were excluded from Mundipharma’s commercialization territory, (b) we may receive regulatory milestone payments of up to $16.0 million, and commercial progress and sales-dependent milestone payments of up to $107.0 million, (c) we will receive tiered double-digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories, and (d) we and Mundipharma will bear our own FOLOTYN development costs.
	We recorded the initial September 2012 fair value of the related drug development liability of $12.3 million, using the discounted cash flow method of the income approach. The fair value of this liability was determined to be $15.8 million as of December 31, 2014 (inclusive of the $7.0 million payment received from Mundipharma). This value is included in the current and long-term portions of “drug development liability” within the accompanying Consolidated Balance Sheets, and it includes our assumptions about personnel needed to perform these research and development activities, third party costs for projected clinical trial enrollment, and patient treatment-related follow up through approximately 2031.

	We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.


		Year Ended December 31,
		Drug			Drug		Total Drug
		Development			Development		Development
		Liability,			Liability,		Liability –
		Current –			Long Term –		FOLOTYN
		FOLOTYN			FOLOTYN
	Balance at December 31, 2013	$	3,119		$	14,623	$	17,742
	Transfer from long term to current in 2014		(21	)		21		—
	(Less): Expenses incurred in 2014		(1,957	)		—		(1,957	)

	Balance at December 31, 2014	$	1,141		$	14,644	$	15,785

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. COMMITMENTS AND CONTINGENCIES
	(a) Facility and Equipment Leases
	We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring May 31, 2019. We also lease our research and development and administrative facility in Irvine, California under a non-cancelable operating lease expiring May 31, 2019, in addition to several other administrative office leases. Each lease agreement contains scheduled rent increases which are accounted for on a straight-line basis. Our total rental expense in 2014, 2013, and 2012 was $1.9 million, $1.2 million, and $0.9 million, respectively.
	Our future minimum lease payments are as follows:


	Year ending December 31,	Operating Lease
		Minimum
		Payments
	2015	$	1,210
	2016		1,150
	2017		1,120
	2018		1,155
	2019		460

		$	5,095

	(b) Licensing Agreements, Co-Development Agreements and Milestone Payments
	Our drug candidates are being developed pursuant to license agreements that provide us with territory-specific rights to its manufacture, sublicense, and sale. We are generally responsible for all development costs, patent filings and maintenance costs, sales and marketing costs, and liability insurance costs. We are also obligated to make certain milestone payments to third parties upon the achievement of regulatory and sales milestones that are specified in these license agreements. We estimate and present a corresponding liability on our Consolidated Balance Sheets when amounts are probable and reasonably estimable. In addition, we are obligated to pay royalties based on our current and future net sales of in-licensed products. Our most significant of these agreements for our commercialized products and products in development are listed and summarized below:

	(i) ZEVALIN U.S.: In-Licensing and development in the U.S.
	In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with a third-party, Cell Therapeutics, Inc. (“CTI”) through our wholly-owned subsidiary, RIT Oncology LLC (“RIT”).
	In accordance with the terms of assumed contracts, we are required to meet specified payment obligations, including a milestone payment to Corixa Corporation of $5.0 million based on ZEVALIN sales in the U.S. (the “Corixa Liability”). This milestone has not yet been met, and $0.1 million for this potential milestone achievement is included within “acquisition-related contingent obligations” in our accompanying December 31, 2014 Consolidated Balance Sheet. Our U.S. net sales-based royalties are in the low to mid-single digits to Genentech, Inc. and mid-single digits to Corixa.
	(ii) ZEVALIN Ex-U.S.: In-License and Asset Purchase Agreement with Bayer Pharma
	In April 2012, through our wholly-owned subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed the acquisition of licensing rights to market ZEVALIN outside of the U.S. from Bayer Pharma AG (“Bayer”). ZEVALIN is currently approved in more than 40 countries outside the U.S. for the treatment of B-cell non-Hodgkin lymphoma, including countries in Europe, Latin America and Asia.
	In consideration for the rights granted under the agreement, concurrent with the closing, we paid Bayer a one-time fee of €19.0 million. Our ex-U.S. net sales-based royalty to Bayer ranges between the single digits to mid-teens. Unless earlier terminated, the term of the agreement continues until the expiration of the last-to-expire patent covering the sale of a licensed product in the relevant country, or 15 years from the date of first commercial sale of the licensed product in such country, whichever is longer.
	(iii) ZEVALIN Ex-U.S.: Out-License Agreement with Dr. Reddy’s
	Effective June 27, 2014, we executed an exclusive License Agreement with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”), for the distribution rights of ZEVALIN within India. The agreement term is fifteen years from the receipt of pending approval of ZEVALIN from the Drug Controller General of India. On December 17, 2014, upon the execution of a supply agreement, an upfront and non-refundable payment of $0.5 million was triggered and was paid to us in February 2015. This upfront payment will be recognized on a straight line basis, upon the first delivery of ZEVALIN product to Dr. Reddy’s within “license fee and service revenue” (aggregating $3 million) on the Consolidated Statement of Operations. Additionally, sales and regulatory milestones will become due to us as they are achieved by Dr. Reddy’s, as well as a 20% royalty on their net sales of ZEVALIN in India.
	(iv) FUSILEV: Amended and Restated In-License Agreement with Merck & Cie AG
	In May 2006, we amended and restated a license agreement with Merck & Cie AG (“Merck”), which we assumed in connection with our March 2006 acquisition of the assets of Targent. Pursuant to the license agreement with Merck, we obtained the exclusive license to use regulatory filings related to FUSILEV and a non-exclusive license under certain patents and know-how to develop, manufacture, use, and sell FUSILEV in the field of oncology in North America in return for a royalty percentage (in the mid-single digits) of net sales. Merck is eligible to receive a $0.2 million payment from us upon the achievement of a FDA approval of an oral form of FUSILEV. This milestone has not yet been met, and no amounts have been accrued in our accompanying Consolidated Balance Sheets for its potential achievement.

	(v) FOLOTYN: In-License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute
	In December 2002, Allos entered into the FOLOTYN License Agreement with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. As a result of Allos becoming our wholly owned subsidiary in September 2012, we are bound by the FOLOTYN License Agreement under which we obtained exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN and its uses. Under the terms of the FOLOTYN License Agreement, we are required to fund all development programs and have sole responsibility for all commercialization activities. In addition, we pay graduated royalties to our licensors based on our (including sub licensees) worldwide annual net sales of FOLOTYN. Royalties are 8% of annual worldwide net sales up to $150 million; 9% of annual worldwide net sales of $150 million through $300 million; and 11% of annual worldwide net sales in excess of $300 million.
	(vi) FOLOTYN: Out-License Agreement with Mundipharma
	We have out-licensed FOLOTYN distribution rights to Munidpharma. We may receive regulatory milestone payments of up to $16 million and commercial progress and sales-dependent milestone payments of up to $107 million. We also receive tiered double-digit royalties based on Mundipharma’s net sales of FOLOTYN within their licensed territories.
	(vii) C-E MELPHALAN: In-License Agreement with Cydex Pharmaceuticals, Inc.
	In March 2013, we completed the acquisition of exclusive global development and commercialization rights to C-E MELPHALAN from Ligand (see Note 10(b)). In April 2014, we reported that C-E MELPHALAN had met its primary endpoint in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma, and as a result, we filed an NDA with the FDA in December 2014.
	We assumed full responsibility for its ongoing clinical and regulatory development program. We are required to pay Ligand additional amounts of up to $66 million, upon achievement of certain regulatory milestones and net sales thresholds, which we have valued at $4.9 million and $4.0 million within “acquisition-related contingent obligations” in our accompanying Consolidated Statements of Operations as of December 31, 2014 and December 31, 2013, respectively. We will also pay royalties of 20% on our net sales of licensed products in all territories.
	(viii) MARQIBO: Agreement with Talon Therapeutics, Inc.
	In July 2013, we completed the acquisition of Talon, through which we obtained exclusive global development and commercialization rights to MARQIBO (see Note 10(a)). As part of this acquisition, we issued the former Talon stockholders contingent value rights (“CVR”) that we have valued and presented on our accompanying Consolidated Balance Sheets as a $2.4 million and $4.3 million liability within “acquisition-related contingent obligations” as of December 31, 2014 and December 31, 2013, respectively. The CVR has a maximum payout of $195 million if all sales and regulatory approval milestones are achieved.
	(ix) APAZIQUONE: License Agreement with Allergan, Inc.
	In October 2008, we entered into an exclusive development and commercialization collaboration agreement with Allergan for APAZIQUONE. Pursuant to the terms of the agreement, Allergan paid us an up-front non-refundable fee of $41.5 million at closing (which we have amortized through revenue within “license fees and service revenue” in full as of December 31, 2013).
	In January 2013, we entered into a second amendment to the license, development, supply and distribution agreement with Allergan to amend the agreement and reacquire the rights originally licensed to Allergan in the U.S., Europe, and other territories in exchange for a tiered single-digit royalty on net sales of certain products containing APAZIQUONE, and relieved Allergan of its development and commercialization obligations.
	As a result of this amendment to the agreement, Allergan has no remaining obligations to us. Additionally, we will be obligated to pay any royalties to certain licensors of underlying intellectual property, as well as to provide indemnification of Allergan for claims arising from the manufacture, development, or commercialization of pharmaceutical products containing APAZIQUONE by us.

	(x) APAZIQUONE: Collaboration Agreement with Nippon Kayaku Co. LTD.
	In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (“Nippon Kayaku”) for the development and commercialization of APAZIQUONE in Asia, except North and South Korea (the “Nippon Kayaku Territory”). In addition, Nippon Kayaku received exclusive rights to APAZIQUONE for the treatment of non-muscle invasive bladder cancer in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct APAZIQUONE clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of APAZIQUONE in the Nippon Kayaku Territory.
	Pursuant to the terms of this agreement, Nippon Kayaku paid us an upfront fee of $15 million (which we have amortized through revenue within “license fees and service revenue” in full as of December 31, 2013). Nippon Kayaku is also obligated to make additional payments to us based on the achievement of certain development, regulatory and commercialization milestones. Under the terms of the agreement, we are entitled to payment of $10 million and $126 million upon achievement of certain regulatory and commercialization milestones, respectively. Also, Nippon Kayaku has agreed to pay us royalties based on a percentage of net sales of the subject products in the defined territory in the mid-teen digits.
	(xi) BELEODAQ: In-Licensing and Collaboration Agreement with TopoTarget
	In February 2010, we entered into a licensing and collaboration agreement with TopoTarget A/S (now Onxeo DK) (“TopoTarget”), as amended in October 2013, for the development and commercialization of BELEODAQ. The agreement provides that we have the exclusive right to manufacture, develop, and commercialize BELEODAQ in North America and India, with an option for China. Pursuant to the terms of this agreement, we paid TopoTarget an upfront fee of $30.0 million in 2010.
	Under continuing terms, all development, including studies, will be conducted under a joint development plan, which we will fund 70% of such costs, and TopoTarget will fund 30%. We have final decision-making authority for all developmental activities in North America and India (and China upon exercise of our option). TopoTarget has final decision-making authority for all developmental activities in all other jurisdictions. In February 2014, upon FDA acceptance of our new drug application, we issued 1.0 million shares of our common stock, and made a $10.0 million milestone payment to TopoTarget. The aggregate payout value of this first milestone at achievement was $17.8 million, and is recognized within “research and development” of the accompanying Consolidated Statement of Operations for the year ended December 31, 2014.
	In July 2014, we received approval from the FDA for BELEODAQ’s use for injection for the treatment of PTCL, and as a result, we paid a second milestone payment to TopoTarget of $25.0 million in November 2014, which we capitalized as an amortizable intangible asset. Other potential milestone payments due upon BELEODAQ regulatory achievements and sales thresholds (aggregating $278.0 million) are not included within “total liabilities” in our accompanying Consolidated Balance Sheets.
	We will pay TopoTarget future royalties in the mid-teen digits based on our net sales of BELEODAQ. The agreement will continue until the expiration of the last royalty payment period in the last country in the defined territory with certain provisions surviving, unless earlier terminated in accordance with its terms.
	(xii) SPI-2012: Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Company
	In January 2012, we entered into a co-development and commercialization agreement, as amended in March 2014, and in October 2014 we entered into a License, Development and Supply Agreement with Hanmi Pharmaceutical Co., Ltd. (“Hanmi”), for SPI-2012, formerly known as “LAPS-GCSF”, a drug for the treatment of chemotherapy induced neutropenia based on Hanmi’s proprietary LAPSCOVERY™ Technology. Under the terms of the agreement, as amended, we have primary financial responsibility for the SPI-2012 development plan. We have worldwide rights, except for Korea, China, and Japan. We will also be responsible for milestone payments related to SPI-2012 regulatory approvals and sales thresholds (aggregating $238 million), which are not included within “total liabilities” in our accompanying Consolidated Balance Sheets. We will pay Hamni royalties in the mid-teen digits on our net sales of SPI-2012.

	(xiii) Poziotinib: In-Licensing Agreement with Hanmi
	In February 2015, we executed an in-license agreement with Hanmi Pharmaceutical Co., Ltd for Poziotinib, a pan-HER inhibitor in Phase 2 clinical trials, for an upfront payment. Poziotinib has shown single agent activity in the treatment of various cancer types during Phase I studies, including breast, gastric, colorectal and lung cancers. Under the terms of this agreement, we received the exclusive rights to commercialize this drug, excluding Korea and China. Hanmi, and its development partners, will bear full responsibility for the on-going Phase 2 trials, and we will bear full financial responsibility of its development thereafter. We will pay Hanmi future regulatory and sales-dependent milestones (aggregating $358 million), which are not included within “total liabilities” in our accompanying Consolidated Balance Sheets. We will pay Hanmi royalties in the low to mid-teen digits on our net sales of Poziotinib.
	(c) Service Agreements
	In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers, and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients.
	At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered.
	(d) Supply Agreements
	We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements (except for certain amounts accrued for within the accompanying Consolidated Financial Statements), and the contracted prices do not exceed their fair market value.
	(e) Employment Agreements
We have entered into an employment agreement with our Chief Executive Officer under which cash compensation and benefits would become payable in the event of termination by us for any reason other than cause, his resignation for good reason, or upon a change in control of our Company.
(f) Deferred Compensation Plan
The Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”) is administered by the Compensation Committee of our Board of Directors and is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended.

The DC Plan is maintained to provide deferred compensation benefits for a select group of our employees (the “DC Participants”). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, and we have the option to make discretionary contributions. At December 31, 2014 and December 31, 2013, this DC Plan liability was $4.7 million and $3.9 million, respectively, and is included within “other long-term liabilities” in the accompanying Consolidated Balance Sheets.
(g) Litigation
We are involved with various legal matters arising in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows or financial condition.
We are presently responding to Abbreviated New Drug Applications (“ANDAs”) filed by companies seeking to launch generic forms of FUSILEV and to certain shareholder suits that purportedly stem from our March 12, 2013 press release, in which we announced anticipated changes in customer ordering patterns of FUSILEV. These complaints allege that, as a result of the March 12, 2013 press release, our stock price declined.
FUSILEV ANDA Litigation
On January 20, 2012, March 2, 2012, June 18, 2014, and January 23, 2015 respectively, we filed suit against Sandoz Inc., Innopharma Inc., Ben Venue Laboratories, Inc., and Amneal Pharmaceuticals, Inc. respectively, following Paragraph IV certifications in connection with their filing separate ANDAs, to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our litigation fees and costs incurred in such matters. On December 9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. On November 24, 2014 the complaint in the Ben Venue case was amended to substitute the original defendant Ben Venue Laboratories, Inc. with successors West-Ward Pharmaceutical Corp. and Eurohealth International SARL. A trial took place in the Sandoz case from January 12, 2015 through January 20, 2015 in the U.S. District Court for the District of Nevada and on February 20, 2015 the district court found the asserted claims of the patent covering FUSILEV invalid. On February 27, 2015 the Company filed its Notice of Appeal. On March 6, 2015 the Court of Appeals for the Federal Circuit temporarily enjoined Sandoz from launching its proposed levo-leucovorin products pending the court’s decision on Spectrum’s motion for an injunction pending appeal. The ultimate outcome of these proceedings is uncertain.
FOLOTYN ANDA Litigation
On June 19, 2014, we filed a lawsuit against five parties resulting from Paragraph IV certifications in connection with four separate ANDAs to manufacture a generic version of FOLOTYN: (1) Teva Pharmaceuticals USA, Inc., (2) Sandoz Inc., (3) Fresenius Kabi USA, LLC, and (4) Dr. Reddy’s Laboratories, Ltd., and Dr. Reddy’s Laboratories, Inc. We filed the lawsuit in the U.S. District Court for the District of Delaware seeking to enjoin the approval of their ANDAs plus recovery of our litigation fees and costs. A trial date of September 12, 2016 has been set in the FOLOTYN lawsuit in the U.S. District Court for the District of Delaware. While we believe our patent rights are strong, the ultimate outcome of such action is uncertain.

Shareholder Litigation
John Perry v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH). This putative consolidated class action raises substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr. Rajesh C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August 8, 2012 to March 12, 2013. The lawsuits allege a violation of Section 10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section 20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company’s March 12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate. On March 21, 2014, the Court entered an order appointing Arkansas Teacher Retirement System as lead plaintiff. On May 20, 2014, Arkansas Teacher Retirement System filed a consolidated amended class action complaint. On July 18, 2014, we filed a motion to dismiss the consolidated amended class action complaint. On September 19, 2014, Arkansas Teacher Retirement System filed an opposition to our motion to dismiss. On October 17, 2014, we filed a reply in support of our motion to dismiss.
Timothy Fik v. Rajesh C. Shrotriya, et al. (Filed April 11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May 28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against certain current and former directors and officers. The complaints generally allege breaches of fiduciary based on conduct relating to the events alleged in the consolidated Perry action. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, and costs and fees. These actions are stayed pending resolution of the federal securities class action.
Hardik Kakadia v. Rajesh C. Shrotriya, et al. (Filed April 23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May 31, 2013; Case Number A-13-682668-C) (collectively the “State Derivative Actions”). These consolidated State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. and are substantially similar to the consolidated federal derivative actions. These actions are stayed pending resolution of the federal securities class action.
(h) SEC Subpoena
On April 1, 2013, we received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed our March 12, 2013 announcement that we anticipated a change in customer ordering patterns of FUSILEV. We continue to cooperate with this SEC investigation, though we cannot predict its outcome, or the timing of resolution.
(i) Notice from HRSA
We received a notice on October 10, 2014 from the U.S. Health Resources and Services Administration, Office of Pharmacy Affairs (“HRSA”). In this notice the HRSA asserts that for at least one of our products with an “orphan drug” designation under section 526 of the Federal Food, Drug, and Cosmetic Act, we did not make the product(s) available for purchase, at the applicable 340B price; as a result, the notice asserts that we have certain undefined amounts due to Covered Entities (see below) based on our previously made and reported product sales.
The 340B price is a discounted price for covered outpatient drugs that manufacturers participating in Medicaid (which includes us) agree to make available to certain providers that participate in the 340B drug discount program (“Covered Entities”). We continue to investigate this matter in order to properly respond to HRSA. Nonetheless, we believe that our pricing to Covered Entities has complied with all applicable legal requirements. Since we only make provisions for liabilities when it is both probable that a liability has been incurred, and the amount can be reasonably estimated, we have not recorded a liability for this pending matter as of December 31, 2014.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	16. INCOME TAXES
	The components of (loss) income before (provision) benefit for income taxes are as follows:


			For the Years Ended
			December 31,
			2014				2013				2012
	United States		$	(37,327	)		$	(30,437	)		$	82,165
	Foreign			(6,205	)			(6,199	)			(2,235	)

	Total		$	(43,532	)		$	(36,636	)		$	79,930


	The provision (benefit) for income taxes consist of the following:


			For the Years Ended
			December 31,
			2014				2013				2012
	Current:
	Federal		$	1,529			$	(8,357	)		$	16,222
	State			126				(691	)			3,412
	Foreign			29				—				—

			$	1,684			$	(9,048	)		$	19,634
	Deferred:
	Federal			495				36,183				(24,013	)
	State			7				(1,637	)			(9,892	)
	Foreign			—				—				—

				502				34,546				(33,905	)

	Total income tax provision (benefit)		$	2,186			$	25,498			$	(14,271	)

	The 2014 income tax provision includes $1.5 million related to the correction of our prior year estimates of carryback of federal net operating losses, book tax differences on acquisition-related liabilities, and credits ineligible for offset against federal income taxes. Management has evaluated the materiality of these adjustments quantitatively and qualitatively, and has concluded that the corrections are immaterial to the accompanying Consolidated Financial Statements, taken as a whole.
	The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:


			2014				2013				2012
	Tax provision (benefit) computed at the federal statutory rate		$	(15,236	)		$	(12,822	)		$	27,975
	State tax, net of federal benefit			66				(246	)			2,442
	Expired tax attributes			—				—				—
	Research credits			(2,134	)			(2,254	)			(2,129	)
	Benefits from credit study			—				—				(4,148	)
	Common stock warrant liability			—				—				—
	Transaction costs			(11	)			880				1,497
	Officers compensation			1,895				2,178				2,908
	Stock based compensation			299				501				134
	Permanent items and other			21,742				(1,080	)			2,111
	Domestic manufacturing deduction			(630	)			767				(1,262	)
	Tax differential on foreign earnings			1,570				1,123				382
	Change in tax rate			(519	)			(283	)			338
	Valuation allowance			(4,856	)			36,734				(44,519	)

	Income tax provision (benefit)		$	2,186			$	25,498			$	(14,271	)

	On December 17, 2014 President Obama signed the Tax Increase Prevention Act., which reinstated the U.S. federal research and development tax credit retroactively from January 1, 2014 through December 31, 2014. The tax benefit resulting from such reinstatement is reflected in our 2014 tax provision.

	Significant components of our deferred tax assets as of December 31, 2014 and 2013 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.


			2014				2013
	Deferred tax assets:
	Net operating loss carry forwards		$	40,505			$	46,482
Research credits			9,045				8,066
Stock based compensation			3,703				3,486
Deferred revenue			1,893				58
Development costs			5,950				6,495
Returns and allowances			4,161				3,117
Other, net			9,082				5,551

Total deferred tax assets before valuation allowance			74,339				73,255
Valuation allowance			(45,983	)			(49,586	)

Total deferred tax assets			28,356				23,669
Deferred tax liabilities:
Basis difference in debt			(907	)			(1,082	)
Depreciation and amortization differences			(34,088	)			(28,096	)

Net deferred tax (liability) asset		$	(6,639	)		$	(5,509	)

At December 31, 2014 and 2013, we recorded a valuation allowance of $46 million and $49.6 million, respectively. The valuation allowance decreased by $3.6 million and increased by $47.8 million, as compared to the prior year periods. The decrease in the valuation allowance in 2014 was due to a $17.2 million adjustment to write off deferred tax assets acquired from Talon that were determined not to be realizable.
At December 31, 2014, we had federal and state net operating loss carryforwards of approximately $106.1 million and $114.4 million, respectively. We have approximately $9.1 million of foreign loss carryforwards that will begin to expire in 2022. The federal and state loss carry forwards begin to expire in 2018 and 2015, respectively, unless previously utilized. At December 31, 2014, we had federal and state tax credits of approximately $10.2 million and $2.4 million, respectively. The federal tax credit carryovers begin to expire in 2027 unless previously utilized. The state research and development credit carryforwards have an indefinite carryover period.
As a result of the prior ownership changes, the utilization of certain net operating loss and research and development tax credit carryforwards including those acquired in connection with the acquisition of Allos and Talon are subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986 and similar state provisions. Any net operating losses or credits that would expire unutilized as a result of Section 382 and 383 limitations have been removed from the table of deferred tax assets and the accompanying disclosures of net operating loss and research and development carryforwards.
Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the de-recognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized.

The following tabular reconciliation summarizes activity related to unrecognized tax benefits:


		2014				2013				2012
Balance at beginning of year		$	2,212			$	5,482			$	3,928
Adjustments related to prior year tax positions			(915	)			(200	)			(527	)
Increases related to current year tax positions			647				648				2,515
Decreases due to settlements			—				(1,227	)			(434	)
Decreases related to prior year tax positions			—				(2,491	)			—

Balance at end of year		$	1,944			$	2,212			$	5,482

During 2014, we continue to believe that our tax positions meet the more-likely-than-not standard required under the recognition phase of the authoritative guidance. However, we consider the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.
Approximately $0.7 million, $0.3 million and $5.2 million of the total unrecognized tax benefits as of December 31, 2014, 2013 and 2012, respectively, would reduce our annual effective tax rate if recognized. Additional amounts in the summary rollforward could impact our effective tax rate if we did not maintain a full valuation allowance on our net deferred tax assets.
We do not expect our unrecognized tax benefits to change significantly over the next 12 months. With a few exceptions, we are no longer subject to U.S. federal, state and local income tax examinations for years before 2009. Our policy is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of operations.

Summary_of_Selected_Quarterly_

Summary of Selected Quarterly Financial Data	12 Months Ended
Summary of Selected Quarterly Financial Data	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Selected Quarterly Financial Data	17. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	Selected quarterly financial data (unaudited) for the year ended December 31, 2014 and 2013 is presented below:


		Quarter Ended (Unaudited)
		March 31			June 30			September 30			December 31
	2014:00:00
	Total revenues	$	40,124		$	46,855		$	47,990		$	51,861
	Operating loss	$	(24,414	)	$	(1,396	)	$	(4,127	)	$	(1,632	)
	Net loss	$	(27,641	)	$	(3,563	)	$	(11,539	)	$	(2,976	)
	Net loss per share, basic	$	(0.44	)	$	(0.06	)	$	(0.18	)	$	(0.05	)
	Net loss per share, diluted	$	(0.44	)	$	(0.06	)	$	(0.18	)	$	(0.05	)
	2013:00:00
	Total revenues	$	38,667		$	33,232		$	42,439		$	41,516
	Operating loss	$	(6,457	)	$	(12,529	)	$	(13,287	)	$	(6,512	)
	Net loss	$	(5,435	)	$	(9,721	)	$	(7,812	)	$	(39,166	)
	Net loss per share, basic	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	Net loss per share, diluted	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	Net loss per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
	Years Ended December 31, 2014, 2013, and 2012


					Additions
					(Reductions)
	Description		Balance at		Additions			Charged		Deductions (1)			Balance at
			Beginning of		(Recovery)			to Other					End of
			Period		to Bad Debt			Accounts					Period
					Expense
			(in thousands)
	Year ended December 31, 2014
	Allowance for doubtful accounts		$	206	$	(85	)		—	$	(1	)	$	120
	Year ended December 31, 2013
	Allowance for doubtful accounts		$	228	$	11			—	$	(33	)	$	206
	Year ended December 31, 2012
	Allowance for doubtful accounts		$	471	$	(128	)		—	$	(115	)	$	228

	-1	Deductions represent the actual write-off of accounts receivable balances.

Description_of_Business_Basis_1

Description of Business, Basis of Presentation, and Operating Segment (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Description of Business	(a) Description of Business
	Spectrum Pharmaceuticals, Inc. and its subsidiaries and other consolidated entities (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biotechnology company, with a primary focus in oncology and hematology. Our strategy is comprised of the (i) commercialization of cancer therapeutics through our U.S. direct sales force and international distributors, (ii) completion of studies for new indications of our marketed products, and (iii) acquisition, development and marketing of a broad and diverse pipeline of late-stage clinical and commercial drug compounds.
	We currently market five drugs for the treatment of cancer:

		•		FUSILEV injection for patients with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

		•		ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma;

		•		FOLOTYN injection for patients with relapsed or refractory PTCL;

		•		MARQIBO injection for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia; and

		•		BELEODAQ® injection for patients with relapsed or refractory PTCL (launched in July 2014).
	We also have ongoing indication expansion studies with several of our marketed products, and a diversified pipeline of product candidates in Phase 2 and Phase 3 clinical studies.
Basis of Presentation	(b) Basis of Presentation
	Principles of Consolidation
	The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned (except for SPC, as discussed below). All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.
	Variable Interest Entity
	We own fifty-percent of Spectrum Pharma Canada (“SPC”), organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this “variable interest entity” (as defined under applicable GAAP). We are obligated to fund all of SPC’s costs and have the sole rights to any revenue it derives. Since we carry the full risks and rewards of SPC, we meet the criteria of being its “primary beneficiary.” Accordingly, SPC’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.
Operating Segment	(c) Operating Segment
	We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2014, 2013, and 2012, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our assets (excluding certain of our bank accounts and intangible asset rights held by our wholly-owned foreign subsidiaries) are located in the U.S.
Revenue Recognition	(i) Revenue Recognition
	(a) Product Sales: We sell our products to wholesalers or distributors (i.e., our customers), except for our U.S. sales of ZEVALIN in which case the end-user (i.e., clinic or hospital) is our customer. Our wholesalers and distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized when title and risk of loss have transferred to our customer, and the following additional criteria are met:

		-1	appropriate evidence of a binding arrangement exists with our customer;

		-2	price is substantially fixed and determinable;

		-3	collection from our customer is reasonably assured;

		-4	our customer’s obligation to pay us is not contingent on resale of the product;

		-5	we do not have significant obligations for future performance to directly bring about the resale of our product; and

		-6	we have a reasonable basis to estimate returns.
	Our gross revenue is reduced by our gross-to-net (“GTN”) estimates each period, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if these estimates are not reasonably determinable at the time of sale. These estimates are based upon information received from external sources (e.g., written and oral information obtained from our wholesalers with respect to their period-end inventory levels and their sales to end-users during the period), in combination with management’s judgments and estimates. Due to the inherent uncertainty of the inputs that these estimates are based upon, the actual amount we incur may be prospectively reported by us as a revenue adjustment in periods after the initial sale is recorded, and could be materially different from our initial estimates.
	Our GTN estimates include the following major categories:
	Product Returns Allowances: Our FUSILEV, MARQIBO, and BELEODAQ customers are permitted to return purchased products for a refund or credit beginning at its expiration date and within six months thereafter. Returned product is generally not resold by us. Returns for expiry of ZEVALIN and FOLOTYN are not contractually or customarily allowed. We estimate potential returns based on historical rates of return.
	Government Chargebacks: Our products are subject to pricing limits under federal government programs. Qualifying entities (i.e., end-users) purchase products from our wholesalers at their qualifying discounted price. The chargeback amount we incur represents the difference between our original sales price to the wholesaler, and the end-user’s applicable discounted purchase price. There may be significant lag time between our original sale to the wholesaler and our receipt of the corresponding government chargeback claims from our wholesalers.
	Prompt Pay Discounts: Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage.
	Commercial Rebates: Rebates are estimated based on our customer’s actual purchase level during the quarterly or annual rebate purchase period, and the corresponding contractual rebate tier we expect each customer to achieve.
	Medicaid Rebates: Our products are subject to state government-managed Medicaid programs, whereby rebates for purchases are issued to participating state governments. These rebates arise when the patient treated with our products is covered under Medicaid. Our calculations related to these Medicaid rebate accruals require us to estimate end-user and patient mix to determine which of our sales will likely be subject to these rebates. There is a significant time lag in us receiving these rebate notices (generally several months after our sale is made). Our estimates are based on our historical claims from participating state governments, as supplemented by management’s judgment.

	Distribution and Data Fees: Distribution, data, and group purchasing organization (GPO) administrative fees are paid to authorized wholesalers of our products (except for U.S. sales of ZEVALIN) for various services, including: contract administration, inventory management, end-user sales data, and product returns processing. These fees are based on a contractually determined percentage of applicable sales.
	(b) License Fees: We recognize revenue for our licensing of intellectual property to third parties (i.e., out-licenses), based on the contractual terms of each agreement and our application of pertinent GAAP. This revenue may be associated with upfront license fees, milestone payments from our licensees’ sales or regulatory achievements, and royalties from our licensees’ sales in applicable territories.
	(c) Service Revenue: We receive fees under certain arrangements for research and development activities, clinical trial management, and supply chain services. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, regulatory approval events, or completion of product delivery in our capacity as an agent in such arrangement. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.
	(d) New Revenue Recognition Standard: ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), was issued in May 2014 for our mandatory adoption beginning January 1, 2017 (no early adoption is permitted under this new revenue recognition standard). ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, the guidance provides that an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation. We continue to evaluate the impact of ASU 2014-09 to our current revenue recognition models for product sales, license fees, and service revenue, as described above.
Cash and Equivalents	(ii) Cash and Cash Equivalents
	Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the original purchase date.
Marketable Securities	(iii) Marketable Securities
	Our marketable securities consist of our holdings in mutual funds and bank certificates of deposit. Since we classify these securities as “available-for-sale” under applicable GAAP, any unrealized gains or losses from their change in value is reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive (Loss) Income. Realized gains and losses on available-for-sale securities are included in “other (expense) income, net” on the accompanying Consolidated Statements of Operations.
Accounts Receivable	(iv) Accounts Receivable
	Our accounts receivables are derived from our product sales, license fees, and service revenue, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
Inventories	(v) Inventories
	We value inventory at the lower of (i) the actual cost to purchase or manufacture it, or (ii) its current market value. Inventory cost is determined on the first-in, first-out method (FIFO). We regularly review our inventory quantities in process of manufacture and on hand, and when appropriate, record a provision for obsolete and excess inventory, which takes into account our sales forecasts by product and corresponding expiry dates. Direct and indirect manufacturing costs related to the production of inventory prior to its FDA approval are expensed through “research and development,” rather than being capitalized to inventory cost.
Property and Equipment	(vi) Property and Equipment
	Our property and equipment is presented at historical cost, less accumulated depreciation. It is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.
Goodwill and Intangible Assets	(vii) Goodwill and Intangible Assets
	Our goodwill represents the excess of our business acquisition cost over the estimated fair value of the net assets acquired in the corresponding transaction. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is evaluated for impairment on an annual basis (as of each October 1st), unless we identify impairment indicators that would require earlier testing. We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s (whether indefinite or definite-lived) carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

		(a)	a significant decrease in the market value of an asset;

		(b)	a significant adverse change in the extent or manner in which an asset is used; or

		(c)	an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.
	Intangible assets with finite useful lives are amortized over their respective patent term or orphan drug exclusivity period on a straight-line basis. We review these assets for potential impairment if/when facts or circumstances suggest that the carrying value of these assets may not be recoverable.
Stock-Based Compensation	(viii) Stock-Based Compensation
	Stock-based compensation expense for equity awards granted to our employees and members of our board of directors is recognized on a straight-line basis over the award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, which estimates those shares expected to be forfeited prior to vesting. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) which carry service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) which carry combined market conditions and service conditions for vesting.

	Calculating and recording stock-based compensation expense requires the use of highly subjective assumptions, including the pre-vesting forfeiture rate, expected dividend payments, expected term of the awards, stock price volatility, and risk-free interest rates. We estimate the expected term of options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant, based on historical volatility of our common stock for a look-back period that corresponds with the expected term. We do not expect to declare any cash dividends in the foreseeable future. We estimate the risk-free interest rate based upon the U.S. Treasury yields in effect at award grant, for a period equaling the stock options’ expected term.
Foreign Currency Translation	(ix) Foreign Currency Translation
	We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the reported balance sheet date. Revenues and expenses are translated using average exchange rates during the reported period. Unrealized gains and losses from the translation of our subsidiaries’ financial statements (that are initially denominated in its foreign functional currency) are included as a separate component of “accumulated other comprehensive loss” in the Consolidated Balance Sheets.
	We record foreign currency transactions, when initially denominated in a currency other than the respective functional currency of our subsidiary, at the prevailing exchange rate on the date of the transaction. Resulting in unrealized and realized gains and losses, including those associated with intercompany loans with our foreign subsidiaries to support their operations, and whose functional currency is not the U.S. dollar, are included in “Other (expense) income, net” within the Consolidated Statements of Operations. This presentation is based on our expectation and intent that these intercompany transactions will be settled in the foreseeable future.
Basic and Diluted Net (Loss) Income per Share	(x) Basic and Diluted Net (Loss) Income per Share
	We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
Income Taxes	(xi) Income Taxes
	Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.
	We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made.
	In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “(Provision) benefit for income taxes” within the Consolidated Statements of Operations and Comprehensive (Loss) Income in the period the notice was received.
Research and Development Costs	(xii) Research and Development Costs
	Research and development costs are expensed as incurred, or as certain milestone payments become due (generally triggered by contractual clinical or regulatory events).
Fair Value Measurements	(xiii) Fair Value Measurements
	We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
	Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.
	Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	“Cash and cash equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of mutual funds that are valued utilizing Level 2 inputs. “Other assets” include our stockholdings of CASI that are valued utilizing Level 1 inputs.
	The fair value of our “drug development liability” within our accompanying Consolidated Balance Sheets was estimated using the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.
	“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with our business combinations. See Note 10(a) for a discussion of contingent value rights granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

Balance_Sheet_Account_Detail_T

Balance Sheet Account Detail (Tables)	12 Months Ended
Balance Sheet Account Detail (Tables)	Dec. 31, 2014
Text Block [Abstract]
Summary of Cash and Cash Equivalents and Marketable Securities	The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:


			Cost			Gross			Gross			Estimated			Cash and		Marketable Securities
						Unrealized			Unrealized			fair Value			equivalents		Marketable Securities
						Gains			Losses								Current		Long
																	Current		Term
	December 31, 2014
	Bank deposits		$	62,997		$	—		$	—		$	62,997		$	62,997	$	—	$	—
	Money market funds			66,945			—			—			66,945			66,945		—		—
	Bank CDs			244			—			—			244			—		244		—
	Mutual funds			3,062			—			—			3,062			—		3,062		—

	Total cash and equivalents and marketable securities		$	133,248		$	—		$	—		$	133,248		$	129,942	$	3,306	$	—

	December 31, 2013
	Bank deposits		$	55,911		$	—		$	—		$	55,911		$	55,911	$	—	$	—
	Money market funds			100,395									100,395			100,395
	Bank CDs			410			—			—			410			—		410		—
	Mutual funds			3,061			—			—			3,061			—		3,061		—

	Total cash and equivalents and marketable securities		$	159,777		$	—		$	—		$	159,777		$	156,306	$	3,471	$	—

Schedule of Property and Equipment Net of Accumulated Depreciation	“Property and equipment, net of accumulated depreciation” consist of the following:


			December 31,
			2014			2013
	Computers and software		$	3,616		$	5,154
	Lab and media equipment			643			1,063
	Office furniture and equipment			344			1,575
	Leasehold improvements			2,847			2,813

	Property and equipment, at cost			7,450			10,605
	(Less): accumulated depreciation and amortization			(6,045	)		(9,070	)

	Property and equipment, net		$	1,405		$	1,535

Components of Inventories	“Inventories” consist of the following:


			December 31,
			2014			2013
	Raw materials		$	1,507		$	1,794
	Work in process			3,979			3,312
	Finished goods			3,714			8,413

	Inventories		$	9,200		$	13,519

Summary of Customers Representing 10% or More of Accounts Receivables	A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2014 and 2013 are as follows:


			Year Ended December 31,
			2014						2013
	Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)		$	36,154			51.1	%	$	18,655			37.7	%
	McKesson Corporation and its affiliates			22,534			31.9	%		15,191			30.7	%
	Integrated Commercialization Solutions, Inc. (“ICS”)			8,432			11.9	%		*			—	%
	Cardinal Health, Inc. and its affiliates			*			—	%		5,097			10.3	%
	All Other Customers			3,638			5.1	%		10,540			21.3	%

	Total Accounts Receivables, net		$	70,758			100	%	$	49,483			100	%


	*	Less than 10%
Schedule of Other Receivables	“Other receivables” consist of (i) amounts we expect to be refunded from taxing authorities for our income taxes paid, relating to fiscal year 2012, and (ii) amounts we expect to be contractually reimbursed from third-parties for certain of our incurred expenses.


			December 31,			December 31,
			2014			2013
	Income tax receivable		$	1,387		$	7,539
	Receivables from third parties for certain of our incurred expenses			4,102			—

			$	5,489		$	7,539

Components of Intangible Assets Net of Accumulated Amortization	“Intangible assets, net of accumulated amortization” consist of the following:


						December 31, 2014
			Historical			Accumulated			Foreign			Impairment			Net Amount		Full		Remaining
			Cost			Amortization			Currency								Amortization		Amortization
									Translation								Period		Period
																	(months)		(months)
	MARQIBO IPR&D (NHL and further ALL indications)		$	17,600		$	—		$	—		$	—		$	17,600		n/a		n/a
	C-E MELPHALAN IPR&D			7,700			—			—			—			7,700		n/a		n/a
	BELEODAQ distribution rights			25,000			(937	)		—			—			24,063		160		154
	MARQIBO distribution rights			26,900			(4,225	)		—			—			22,675		81		63
	FOLOTYN distribution rights			118,400			(20,030	)		—			—			98,370		152		125
	ZEVALIN distribution rights – U.S.			41,900			(27,134	)		—			—			14,766		122		48
	ZEVALIN distribution rights – Ex-U.S.			23,490			(7,402	)		(2,162	)		—			13,926		95		62
	FUSILEV distribution rights			16,778			(6,270	)		—			—			10,508		84		40
	FOLOTYN out-license*			27,900			(6,385	)		—			(1,023	)		20,492		110		91

	Total intangible assets		$	305,668		$	(72,383	)	$	(2,162	)	$	(1,023	)	$	230,100


	*	On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., FOLOTYN rights). We determined that an impairment of the FOLOTYN out-license rights to Mundipharma of $1.0 million resulted from this amendment.



						December 31, 2013
			Historical			Accumulated			Foreign			Impairment			Net Amount
			Cost			Amortization			Currency
									Translation
	MARQIBO IPR&D (NHL and further ALL indications)		$	17,600		$	—		$	—		$	—		$	17,600
	C-E MELPHALAN IPR&D			7,700			—			—			—			7,700
	MARQIBO distribution rights			26,900			(1,107	)		—			—			25,793
	ZEVALIN distribution rights – U.S.			41,900			(23,455	)		—			—			18,445
	ZEVALIN distribution rights – Ex-U.S.			23,490			(5,343	)		682			—			18,829
	FUSILEV distribution rights			16,778			(4,821	)		—			—			11,957
	FOLOTYN out-license			27,900			(3,662	)		—			(1,023	)		23,215
	FOLOTYN distribution rights			118,400			(10,587	)		—			—			107,813

	Total intangible assets		$	280,668		$	(48,975	)	$	682		$	(1,023	)	$	231,352

Estimated Intangible Asset Amortization Expense	Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:


	Years Ending December 31
	2015			25,937
	2016			25,937
	2017			25,937
	2018			25,937
	2019			23,332
	2020 and thereafter			77,720

			$	204,800

Schedule of Goodwill	“Goodwill” is comprised of the following (by source):


			December 31,			December 31,
			2014			2013
	Acquisition of Talon		$	10,526		$	10,526
	Acquisition of ZEVALIN Ex-U.S. distribution rights			2,525			2,525
	Acquisition of Allos			5,346			5,346
	Foreign currency exchange translation effects			(202	)		104

			$	18,195		$	18,501

Summary of Other Assets	“Other assets” are comprised of the following:


			December 31,			December 31,
			2014			2013
	Equity securities (see Note 11)		$	8,501		$	3,593
	Supplies			234			190
	2018 Convertible Notes issuance costs			2,171			3,432
	Executive officer life insurance – cash surrender value			6,958			5,362

			$	17,864		$	12,577

Schedule of Accounts Payable and Other Accrued Obligations	Accounts payable and other accrued obligations are comprised of the following:


			December 31,
			2014			2013
	Trade payables		$	8,994		$	12,796
	Accrued research and development expenses			5,423			6,433
	Accrued selling, general and administrative expenses			10,154			8,870
	Accrued rebates			41,782			28,893
	Accrued product royalty			5,182			9,498
	Allowance for returns			1,135			2,900
	Accrued data and distribution fees			3,952			2,430
	Accrued GPO administrative fees			3,222			2,327
	Inventory management fee			1,110			616
	Allowance for chargebacks			4,040			5,074

			$	84,994		$	79,837

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations	Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:


	Description		Rebates and			Data and			Returns
			Chargebacks			Distribution,
						GPO Fees, and
						Inventory
						Management
						Fees
	Balance as of December 31, 2012		$	26,176		$	14,149		$	5,056
	Add: provisions (recovery)			63,609			19,067			(2,034	)
	(Less): credits or actual allowances			(55,818	)		(27,843	)		(122	)

	Balance as of December 31, 2013			33,967			5,373			2,900
	Add: provisions (recovery)			76,636			21,330			(78	)
	(Less): credits or actual allowances			(64,781	)		(18,419	)		(1,687	)

	Balance as of December 31, 2014		$	45,822		$	8,284		$	1,135
Summary of Other Long-Term Liabilities	Other long-term liabilities are comprised of the following:


			December 31,
			2014			2013
	Accrued executive deferred compensation		$	4,694		$	3,949
	Deferred rent (non-current portion)			364			366
	Business acquisition liability			300			298
	Other tax liabilities			730			1,352

			$	6,088		$	5,965

GrosstoNet_Product_Sales_Table

Gross-to-Net Product Sales (Tables)	12 Months Ended
Gross-to-Net Product Sales (Tables)	Dec. 31, 2014
Text Block [Abstract]
Reconciliation of Gross to Net Product Sales	The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:


		2014			2013			2012
	Gross product sales	$	284,685		$	224,301		$	383,817
	Rebates and chargebacks		(76,636	)		(63,610	)		(91,059	)
	Data, distribution and GPO administration fees		(21,330	)		(19,067	)		(32,793	)
	Prompt pay discount		(260	)		(183	)		(4,814	)
	Product returns allowance		78			2,034			(159	)

	Product sales, net	$	186,537		$	143,475		$	254,992

Net_Product_Sales_by_Geographi1

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers (Tables)	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Schedule of Net Product Sales by Geography	The below table presents our net product sales by geography for the years ended December 31, 2014, 2013, and 2012:
	Net Product Sales by Geographic Region


			Year Ended December 31,
			2014				2013				2012
	United States		$	177,979	95.4	%	$	133,462	93	%	$	245,697	96.4	%

	International:
	Europe (ZEVALIN only)			3,357	1.8	%		3,953	2.8	%		3,113	1.2	%
	Asia Pacific (ZEVALIN only)			5,201	2.8	%		6,060	4.2	%		6,182	2.4	%

	Total International			8,558	4.6	%		10,013	7	%		9,295	3.6	%

	Net product sales		$	186,537	100	%	$	143,475	100	%	$	254,992	100	%

Schedule of Net Product Sales by Product Line	Net Sales by Product
	The below table presents our net product sales by product line for the years ended December 31, 2014, 2013, and 2012:


			Year Ended December 31,
			2014				2013				2012
	FUSILEV		$	105,608	56.6	%	$	68,397	47.7	%	$	204,253	80.1	%
	FOLOTYN			47,556	25.5	%		44,370	30.9	%		20,412	8	%
	ZEVALIN			22,169	11.9	%		29,393	20.5	%		30,327	11.9	%
	MARQIBO			6,328	3.4	%		1,315	0.9	%		—	—	%
	BELEODAQ			4,876	2.6	%		—	—	%		—	—	%

	Net product sales		$	186,537	100	%	$	143,475	100	%	$	254,992	100	%

Summary of Customers Representing 10% or More of Gross Product Sales	Gross Product Sales by Customer
	The below table presents the customers that represent 10% or more of our gross product sales in 2014, 2013, and 2012:


			Year Ended December 31,
			2014				2013				2012
	Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)		$	115,079	40	%	$	79,497	35.4	%	$	101,712	26.5	%
	McKesson Corporation and its affiliates			93,656	32.1	%		44,350	19.8	%		89,046	23.2	%
	Integrated Commercialization Solutions, Inc. (“ICS”)			*	—	%		35,548	15.8	%		74,461	19.4	%
	Cardinal Health, Inc. and its affiliates			*	—	%		*	—	%		60,259	15.7	%
	All Other Customers			75,950	27.9	%		64,906	29	%		58,339	15.2	%

	Gross product sales		$	284,685	100	%	$	224,301	100	%	$	383,817	100	%


	*	Less than 10%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense	Stock-based compensation expense included within operating expenses for years ended December 31, 2014, 2013, and 2012 was as follows:


			Year Ended December 31,
			2014			2013		2012
	Selling, general and administrative		$	10,053		$	10,762	$	13,041
	Research and development			1,756			2,017		1,843

	Total		$	11,809		$	12,779	$	14,884

Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model	The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:


			Year Ended December 31,
			2014		2013	2012
	Expected option life (in years) (a)		4.95		4.95	4.5
	Risk-free interest rate (b)		0.58% - 1.52%		0.35% - 0.78%	0.34% - 0.51%
	Volatility (c)		48.9% - 62.1%		58.3% -71.5%	64.2% - 73.6%
	Dividend yield (d)		0%		0%	0%
	Weighted-average grant-date fair value per stock option		$3.49		$4.66	$6.20

	(a)	Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
	(b)	Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
	(c)	Measured using our historical stock price for a period equal to stock options’ expected term.
	(d)	We do not expect to declare any cash dividends in the foreseeable future.
Summary of Stock Option Activity	Stock option activity during the years ended December 31, 2014, 2013, and 2012 is as follows:


			Number of			Weighted-		Weighted-		Aggregate
			Shares			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price/Share		Contractual
								Term (Years)
	Outstanding — December 31, 2011			10,185,521		$	5.46
	Granted			1,821,915			11.57
	Exercised			(1,287,430	)		4.52			$	11,500	(1)
	Forfeited			(316,825	)		7.93
	Expired			(3,916	)		7.69

	Outstanding — December 31, 2012			10,399,265			6.57
	Granted			2,041,300			8.92
	Exercised			(825,884	)		4.4			$	3,435	(1)
	Forfeited			(202,882	)		8.22
	Expired			(82,581	)		8.91

	Outstanding — December 31, 2013			11,329,218			7.1
	Granted			2,576,292			7.6
	Exercised			(485,260	)		4.77			$	1,629	(1)
	Forfeited			(557,109	)		9.65
	Expired			(214,039	)		10.7

	Outstanding — December 31, 2014			12,649,102		$	7.12		6.61	$	11,679	(2)

	Vested (exercisable) — December 31, 2014			9,134,760		$	6.62		5.66	$	11,678	(2)

	Unvested (unexercisable) — December 31, 2014			3,514,342		$	8.42		9.07	$	766	(2)


	-1	Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
	-2	Represents the total difference between our closing stock price on the last trading day of 2014 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2014. The amount of intrinsic value will change based on the fair market value of our stock.
Summary of Stock Option Grants	The following table summarizes information with respect to stock option grants as of December 31, 2014:


			Outstanding							Exercisable
	Exercise Price		Granted Stock			Weighted-		Weighted-		Granted			Weighted-
			Options			Average		Average		Stock			Average
			Outstanding			Remaining		Exercise		Options			Exercise
						Contractual		Price		Exercisable			Price
						Life (Years)
	$0.92 – 3.15			1,135,594			3.47	$	2.19		1,135,594		$	2.19
	$3.16 – 4.95			1,673,317			4.89		4.24		1,673,317			4.24
	$4.96 – 6.9			2,708,119			4.42		6.27		2,701,899			6.27
	$6.91 – 8.99			4,539,130			8.41		7.86		1,983,129			8.09
	$9.00 – 16.32			2,592,942			8.21		10.75		1,640,821			10.94

				12,649,102			6.61	$	7.12		9,134,760		$	6.62

Summary of Restricted Stock Award Activity	A summary of restricted stock award activity is as follows:


			Number of			Weighted Average
			Restricted Stock			Fair Value per
			Awards			Share at Grant
						Date
	Unvested as of December 31, 2011			952,525		$	10.11
	Granted			586,639			11.76
	Vested			(472,160	)		10.26
	Forfeited			(32,400	)		9.57

	Unvested — December 31, 2012			1,034,604			11
	Granted			523,800			8.74
	Vested			(501,660	)		9.72
	Forfeited			(49,625	)		10.6

	Unvested — December 31, 2013			1,007,119			10.09
	Granted			581,194			7.52
	Vested			(578,985	)		10.24
	Forfeited			(185,111	)		9.88

	Unvested — December 31, 2014			824,217		$	8.22


Fair Value of Restricted Stock Awards
			2014			2013		2012
	Restricted stock expense		$	3,830		$	4,202	$	6,500
Issued Shares of Common Stock	We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employees’ annual 401(k) contributions, as summarized below:


			2014			2013		2012
	Shares of common stock issued			133,734			99,359		56,254
	Match contribution value*		$	1,028		$	860	$	691

	*	Represents our stock price on the date of the common stock issuance multiplied by the number of shares of common stock issued.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Equity [Abstract]
Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted	As of December 31, 2014, 24.9 million shares of our common stock were issuable upon conversion, or exercise of rights granted (regardless of whether in or out-of-the-money), as summarized below:


	Conversion of Series E Preferred Stock		40,000
	2018 Convertible Notes		11,400,000
	Exercise of issued employee stock options		12,649,102
	Exercise of issued warrants		445,000
	Management incentive plan restricted stock units		346,500

	Total common shares		24,880,602

Summary of Warrant Activity	A summary of warrant activity is as follows:


		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding — December 31, 2011		445,000		$	5.04
	Exercised		(50,000	)		1.79

	Outstanding — December 31, 2012		395,000		$	5.45
	Granted		50,000			7.51

	Outstanding — December 31, 2013		445,000		$	6.39
	Granted		—			—

	Outstanding — December 31, 2014		445,000		$	6.39

	Exercisable — December 31, 2014		445,000		$	6.39

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	12 Months Ended
Net (Loss) Income Per Share (Tables)	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Net (Loss) Income Per Share	Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2014, 2013, and 2012:


		Year Ended December 31,
		2014			2013			2012
	Net (loss) income	$	(45,719	)	$	(62,134	)	$	94,201
	Weighted average shares—basic		64,708,163			60,729,128			58,588,916
	Net (loss) income per share—basic	$	(0.71	)	$	(1.02	)	$	1.61
	Weighted average shares—diluted		64,708,163			60,729,128			64,637,256
	Net (loss) income per share—diluted	$	(0.71	)	$	(1.02	)	$	1.46
Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share	The following summarizes the amounts used in computing basic and diluted net income per share, for the year ended 2012:


		Net Income			Weighted-			Net
		(numerator)			Average			Income
					Shares			Per Share
					Outstanding
					(Denominator)
	Year Ended December 31, 2012
	Basic net income per share:	$	94,201			58,588,916		$	1.61

	Diluted net income per share:
	Dilutive preferred shares					40,000
	Dilutive common stock options					4,749,299
	Incremental common stock assumed issued on exercise of in-the-money warrants					224,437
	Unvested restrictive stock awards					1,034,604

	Diluted net income per share	$	94,201			64,637,256		$	1.46

Schedule of Securities Excluded from Calculation of Net (Loss) per Share	Certain of our outstanding securities were excluded from the above calculation of net loss per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net loss per share:


		Year Ended December 31,
		2014			2013			2012
	2018 Convertible Notes		11,401,284			343,600			—
	Common stock options		2,173,916			2,934,625			—
	Restricted stock awards		824,217			1,007,119			—
	Common stock warrants		120,702			160,816			—
	Preferred stock		40,000			40,000			—

	Total		14,560,119			4,486,160			—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Summary of Asset and Liability Fair Values	The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories:


		December 31, 2014
		Fair Value Measurements
		Level 1			Level 2		Level 3		Total
	Assets:
	Bank CDs	$	—		$	244	$	—	$	244
	Money market currency funds		—			66,945		—		66,945
	Equity securities		9,959			—		—		9,959
	Mutual funds		—			3,062		—		3,062
	Deferred compensation investments, including life insurance cash surrender value		—			6,958		—		6,958

		$	9,959		$	77,209	$	—	$	87,168

	Liabilities:
	Deferred executive compensation liability		—			4,694		—		4,694
	Deferred development costs		—			—		15,785		15,785
	Ligand Contingent Consideration		—			—		4,901		4,901
	Talon CVR		—			—		2,379		2,379
	Corixa Liability		—			—		62		62

		$	—		$	4,694	$	23,127	$	27,821



		December 31, 2013
		Fair Value Measurements
		Level 1			Level 2		Level 3		Total
	Assets:
	Bank CDs	$	—		$	410	$	—	$	410
	Money market currency funds					100,395		—		100,395
	Mutual funds		—			3,061		—		3,061
	Deferred compensation investments, including life insurance cash surrender value		—			5,361		—		5,361
	Equity securities		3,593			—		—		3,593

		$	3,593		$	109,227	$	—	$	112,820

	Liabilities:
	Deferred executive compensation liability		—			3,949		—		3,949
	Deferred development costs		—			—		17,742		17,742
	Ligand Contingent Consideration		—			—		4,000		4,000
	Talon CVR		—			—		4,329		4,329

		$	—		$	3,949	$	26,071	$	30,020

Activity of Level 3 Inputs Measured on Recurring Basis	The following presents a roll forward of our liabilities for which we utilize Level 3 inputs in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “drug development liability, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.


		Fair Value Measurements of
		Unobservable Inputs
		(*Level 3*)
	Balance at December 31, 2012	$	14,520
	Transfers in (out)		—
	Deferred development costs		5,509
	Deferred payment contingency		(2,287	)
	Ligand Contingent Consideration		4,000
	Talon CVR		4,329

	Balance at December 31, 2013	$	26,071
	Transfers in (out)		—
	Deferred development costs (see Note 14)		(1,957	)
	Deferred payment contingency (see Note 14)		—
	Ligand Contingent Consideration (see Note 10(b))		901
	Talon CVR (see Note 10(a))		(1,950	)
	Corixa Liability (see Note 15(b)(i))		62

	Balance at December 31, 2014	$	23,127

Business_Combinations_and_Cont1

Business Combinations and Contingent Consideration (Tables)	12 Months Ended
Business Combinations and Contingent Consideration (Tables)	Dec. 31, 2014
Summary of Allocation of Total Purchase Price to Net Assets Acquired	The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:


	Cash and equivalents		$	131
	Inventory			611
	Prepaid expenses and other current assets			109
	Property and equipment			30
	Identifiable intangible assets			44,500

	Total assets acquired			45,381

	Accounts payable & accrued liabilities			5,231
	Deferred tax liability			6,576

	Total liabilities assumed			11,807

	Net assets acquired		$	33,574

	Goodwill		$	10,526

Amortization Period for such Intangible Assets Acquired	The acquired intangible assets consisted of (i) developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and (ii) MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) and other potential indications, as summarized in the table below:


			Value of			Amortization
			Intangible			Period*
			Assets
			Acquired
	Developed technology —MARQIBO for ALL		$	26,900			81 months
	IPR&D —MARQIBO for NHL and other potential indications			17,600			(1	)

	Total identifiable intangible assets		$	44,500


	*	Recognized on a straight-line basis.
	-1	IPR&D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but is periodically tested for impairment.
Talon Therapeutics, Inc. [Member]
Change in Fair Value of Contingent Consideration Related to Acquisition	Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations, and the CVR is presented at each reporting period within “acquisition-related contingent obligations” within long-term liabilities on the accompanying Consolidated Balance Sheets .


			Fair Value
			of Talon
			CVR
	December 31, 2013		$	4,329
	Fair value adjustment for the year ended December 31, 2014			(1,950	)

	December 31, 2014		$	2,379

Acquisition-Date Fair Value of Consideration Transferred	The acquisition-date fair value of the consideration transferred consisted of the following items:


	Cash consideration		$	3,000
	Ligand Contingent Consideration			4,700

	Total purchase consideration		$	7,700

Melphalan license [Member]
Change in Fair Value of Contingent Consideration Related to Acquisition	Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations.


			Fair Value of
			Ligand
			Contingent
			Consideration
	December 31, 2013		$	4,000
	Fair value adjustment for year ended December 31, 2014			901

	December 31, 2014		$	4,901

Summary of Allocation of Total Purchase Price to Net Assets Acquired	The allocation of the total purchase price to the net assets acquired is as follows:


	IPR&D—C-E MELPHALAN rights		$	7,700

OutLicense_of_Marqibo_Zevalin_1

Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory (Tables)	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date	The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following:


	CASI common stock (a) (5.4 million shares)		$	8,649	(a)
	CASI secured promissory note due March 17, 2016, net of fair value discount (b) ($1.5 million face value and 0.5% annual coupon)			1,310	(b)

	Total consideration received		$	9,959	(c)


		•		Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $8.5 million as of December 31, 2014 within “other assets” (rather than “marketable securities”) on our accompanying Consolidated Balance Sheets. The change in the value of these securities at each reporting period is included in “other comprehensive income (loss), net” on the accompanying Consolidated Statement of Comprehensive Income (Loss).

		•		Present value estimated using the terms of the $1.5 million promissory note, and the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014.

		•		Presented within “deferred revenue” in the accompanying Consolidated Balance Sheets as of December 31, 2014.

Convertible_Senior_Notes_Table

Convertible Senior Notes (Tables)	12 Months Ended
Convertible Senior Notes (Tables)	Dec. 31, 2014
Text Block [Abstract]
Carrying Value of 2018 Convertible Notes	The carrying value of the 2018 Convertible Notes as of December 31, 2014 is summarized as follows:


	Principal amount	$	120,000
	(Less): Unamortized debt discount (amortized through December 2018)		(23,702	)

	December 31, 2014	$	96,298

Components of Total Interest Expense, Net Recognized	The following table sets forth the components of total “interest expense, net” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the years ended December 31, 2014 and 2013:


		Year Ended December 31,
		2014			2013
	Contractual coupon interest expense	$	3,300		$	73
	Amortization of debt issuance costs		599			43
	Accretion of debt discount		4,818			101

	Total	$	8,717		$	217
	Effective interest rate		8.66	%		8.59	%

Mundipharma_Agreement_Tables

Mundipharma Agreement (Tables)	12 Months Ended
Mundipharma Agreement (Tables)	Dec. 31, 2014
Text Block [Abstract]
Schedule of Drug Development Liability Adjustments	We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.


		Year Ended December 31,
		Drug			Drug		Total Drug
		Development			Development		Development
		Liability,			Liability,		Liability –
		Current –			Long Term –		FOLOTYN
		FOLOTYN			FOLOTYN
	Balance at December 31, 2013	$	3,119		$	14,623	$	17,742
	Transfer from long term to current in 2014		(21	)		21		—
	(Less): Expenses incurred in 2014		(1,957	)		—		(1,957	)

	Balance at December 31, 2014	$	1,141		$	14,644	$	15,785

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Our future minimum lease payments are as follows:


	Year ending December 31,	Operating Lease
		Minimum
		Payments
	2015	$	1,210
	2016		1,150
	2017		1,120
	2018		1,155
	2019		460

		$	5,095

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of (Loss) Income before (Provision) Benefit for Income Taxes	The components of (loss) income before (provision) benefit for income taxes are as follows:


		For the Years Ended
		December 31,
		2014			2013			2012
	United States	$	(37,327	)	$	(30,437	)	$	82,165
	Foreign		(6,205	)		(6,199	)		(2,235	)

	Total	$	(43,532	)	$	(36,636	)	$	79,930

Provision (Benefit) for Income Taxes	The provision (benefit) for income taxes consist of the following:


		For the Years Ended
		December 31,
		2014			2013			2012
	Current:
	Federal	$	1,529		$	(8,357	)	$	16,222
	State		126			(691	)		3,412
	Foreign		29			—			—

		$	1,684		$	(9,048	)	$	19,634
	Deferred:
	Federal		495			36,183			(24,013	)
	State		7			(1,637	)		(9,892	)
	Foreign		—			—			—

			502			34,546			(33,905	)

	Total income tax provision (benefit)	$	2,186		$	25,498		$	(14,271	)

Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes	The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:


		2014			2013			2012
	Tax provision (benefit) computed at the federal statutory rate	$	(15,236	)	$	(12,822	)	$	27,975
	State tax, net of federal benefit		66			(246	)		2,442
	Expired tax attributes		—			—			—
	Research credits		(2,134	)		(2,254	)		(2,129	)
	Benefits from credit study		—			—			(4,148	)
	Common stock warrant liability		—			—			—
	Transaction costs		(11	)		880			1,497
	Officers compensation		1,895			2,178			2,908
	Stock based compensation		299			501			134
	Permanent items and other		21,742			(1,080	)		2,111
	Domestic manufacturing deduction		(630	)		767			(1,262	)
	Tax differential on foreign earnings		1,570			1,123			382
	Change in tax rate		(519	)		(283	)		338
	Valuation allowance		(4,856	)		36,734			(44,519	)

	Income tax provision (benefit)	$	2,186		$	25,498		$	(14,271	)

Components of Company's Deferred Tax Assets	Significant components of our deferred tax assets as of December 31, 2014 and 2013 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.


		2014			2013
	Deferred tax assets:
	Net operating loss carry forwards	$	40,505		$	46,482
	Research credits		9,045			8,066
	Stock based compensation		3,703			3,486
	Deferred revenue		1,893			58
	Development costs		5,950			6,495
	Returns and allowances		4,161			3,117
	Other, net		9,082			5,551

	Total deferred tax assets before valuation allowance		74,339			73,255
	Valuation allowance		(45,983	)		(49,586	)

	Total deferred tax assets		28,356			23,669
	Deferred tax liabilities:
	Basis difference in debt		(907	)		(1,082	)
	Depreciation and amortization differences		(34,088	)		(28,096	)

	Net deferred tax (liability) asset	$	(6,639	)	$	(5,509	)

Summary of Unrecognized Tax Benefits	The following tabular reconciliation summarizes activity related to unrecognized tax benefits:


		2014			2013			2012
	Balance at beginning of year	$	2,212		$	5,482		$	3,928
	Adjustments related to prior year tax positions		(915	)		(200	)		(527	)
	Increases related to current year tax positions		647			648			2,515
	Decreases due to settlements		—			(1,227	)		(434	)
	Decreases related to prior year tax positions		—			(2,491	)		—

	Balance at end of year	$	1,944		$	2,212		$	5,482

Summary_of_Selected_Quarterly_1

Summary of Selected Quarterly Financial Data (Tables)	12 Months Ended
Summary of Selected Quarterly Financial Data (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Selected Quarterly Financial Data	Selected quarterly financial data (unaudited) for the year ended December 31, 2014 and 2013 is presented below:


		Quarter Ended (Unaudited)
		March 31			June 30			September 30			December 31
	2014:00:00
	Total revenues	$	40,124		$	46,855		$	47,990		$	51,861
	Operating loss	$	(24,414	)	$	(1,396	)	$	(4,127	)	$	(1,632	)
	Net loss	$	(27,641	)	$	(3,563	)	$	(11,539	)	$	(2,976	)
	Net loss per share, basic	$	(0.44	)	$	(0.06	)	$	(0.18	)	$	(0.05	)
	Net loss per share, diluted	$	(0.44	)	$	(0.06	)	$	(0.18	)	$	(0.05	)
	2013:00:00
	Total revenues	$	38,667		$	33,232		$	42,439		$	41,516
	Operating loss	$	(6,457	)	$	(12,529	)	$	(13,287	)	$	(6,512	)
	Net loss	$	(5,435	)	$	(9,721	)	$	(7,812	)	$	(39,166	)
	Net loss per share, basic	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	Net loss per share, diluted	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)

Description_of_Business_Basis_2

Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Segment
Segment Reporting Information [Line Items]
Number of reportable operating segment	1
Spectrum Pharma Canada [Member]
Segment Reporting Information [Line Items]
Ownership interest, percentage	50.00%

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Number of months customers are allowed to return products	6 months
Cash and equivalents maturities period	3 months

Balance_Sheet_Account_Detail_S

Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Investments [Line Items]
Cash and cash equivalents, Marketable securities, Cost	$133,248	$159,777
Cash and cash equivalents, Marketable securities, Gross Unrealized Gains	0	0
Cash and cash equivalents, Marketable securities, Gross Unrealized Losses	0	0
Cash and cash equivalents, Marketable securities, Estimated fair Value	133,248	159,777
Cash and cash equivalents	129,942	156,306	139,698	121,202
Marketable Security, Current	3,306	3,471
Bank Deposits [Member]
Schedule of Investments [Line Items]
Bank deposits, Cost	62,997	55,911
Bank deposits, Gross Unrealized Gains	0	0
Bank deposits, Gross Unrealized Losses	0	0
Bank deposits, Estimated fair Value	62,997	55,911
Cash and cash equivalents	62,997	55,911
Money Market Funds [Member]
Schedule of Investments [Line Items]
Marketable security, Amortized Cost	66,945	100,395
Marketable security, Gross Unrealized Gains	0	0
Marketable security, Gross Unrealized Losses	0	0
Marketable security, Estimated fair Value	66,945	100,395
Cash and cash equivalents	66,945	100,395
Bank CDs [Member]
Schedule of Investments [Line Items]
Marketable security, Amortized Cost	244	410
Marketable security, Gross Unrealized Gains	0	0
Marketable security, Gross Unrealized Losses	0	0
Marketable security, Estimated fair Value	244	410
Marketable Security, Current	244	410
Mutual Funds [Member]
Schedule of Investments [Line Items]
Marketable security, Amortized Cost	3,062	3,061
Marketable security, Gross Unrealized Gains	0	0
Marketable security, Gross Unrealized Losses	0	0
Marketable security, Estimated fair Value	3,062	3,061
Marketable Security, Current	$3,062	$3,061

Balance_Sheet_Account_Detail_A

Balance Sheet Account Detail - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Investments In Marketable Securities [Line Items]
Securities in continuous unrealized loss position, period	Longer than one year.
Depreciation expense	$1,100,000	$1,200,000	$1,200,000
Property and equipment, at cost	7,450,000	10,605,000
(Less): Accumulated depreciation	-6,045,000	-9,070,000
Intangible assets, net	230,100,000	231,352,000
Intangible assets, impairment	0
Intangible asset amortization expense	24,300,000	21,200,000	8,800,000
Unrealized gains and losses from available-for-sale securities	2,200,000
MARQIBO IPR&D (NHL and further ALL indications) [Member]
Schedule Of Investments In Marketable Securities [Line Items]
Intangible assets, net	17,600,000	17,600,000
C-E MELPHALAN IPR&D [Member]
Schedule Of Investments In Marketable Securities [Line Items]
Intangible assets, net	7,700,000	7,700,000
Adjusted Property And Equipment [Member]
Schedule Of Investments In Marketable Securities [Line Items]
Property and equipment, at cost	4,200,000
(Less): Accumulated depreciation	($4,000,000)

Balance_Sheet_Account_Detail_S1

Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$7,450	$10,605
(Less): accumulated depreciation and amortization	-6,045	-9,070
Property and equipment, net	1,405	1,535
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	3,616	5,154
Lab and media equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	643	1,063
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	344	1,575
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$2,847	$2,813

Balance_Sheet_Account_Detail_C

Balance Sheet Account Detail - Components of Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$1,507	$1,794
Work in process	3,979	3,312
Finished goods	3,714	8,413
Inventories	$9,200	$13,519

Balance_Sheet_Account_Detail_S2

Balance Sheet Account Detail - Summary of Customers Representing 10% or More of Accounts Receivables (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net	70,758	49,483
Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net	36,154	18,655
McKesson Corporation and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net	22,534	15,191
Integrated Commercialization Solutions, Inc. (ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net	8,432
Cardinal Health, Inc. and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net		5,097
All Other Customers [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivables, net	3,638	10,540
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	100.00%	100.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	51.10%	37.70%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| McKesson Corporation and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	31.90%	30.70%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Integrated Commercialization Solutions, Inc. (ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	11.90%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Cardinal Health, Inc. and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net		10.30%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| All Other Customers [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	5.10%	21.30%

Balance_Sheet_Account_Detail_S3

Balance Sheet Account Detail - Summary of Customers Representing 10% or More of Accounts Receivables (Parenthetical) (Detail) (Customer Concentration Risk [Member], Accounts Receivable [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	100.00%	100.00%
Integrated Commercialization Solutions, Inc. (ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	11.90%
Cardinal Health, Inc. and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net		10.30%
Maximum [Member] \| Integrated Commercialization Solutions, Inc. (ICS) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net	10.00%
Maximum [Member] \| Cardinal Health, Inc. and its affiliates [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of accounts receivable, net		10.00%

Balance_Sheet_Account_Detail_S4

Balance Sheet Account Detail - Schedule of Other Receivables (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Receivables [Abstract]
Income tax receivable	$1,387	$7,539
Receivables from third parties for certain of our incurred expenses	4,102
Other receivables	$5,489	$7,539

Balance_Sheet_Account_Detail_C1

Balance Sheet Account Detail - Components of Intangible Assets Net of Accumulated Amortization (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Product Rights [Line Items]
Historical Cost	$305,668	$280,668
Accumulated Amortization	-72,383	-48,975
Foreign Currency Translation	-2,162	682
Impairment	-1,023	-1,023
Net Amount	230,100	231,352
FOLOTYN distribution rights [Member]
Product Rights [Line Items]
Historical Cost	118,400	118,400
Accumulated Amortization	-20,030	-10,587
Foreign Currency Translation	0	0
Net Amount	98,370	107,813
Full Amortization Period (months)	152 months
Remaining Amortization Period (months)	125 months
MARQIBO IPR&D (NHL and further ALL indications) [Member]
Product Rights [Line Items]
Historical Cost	17,600	17,600
Net Amount	17,600	17,600
BELEODAQ distribution rights [Member]
Product Rights [Line Items]
Historical Cost	25,000
Accumulated Amortization	-937
Net Amount	24,063
Full Amortization Period (months)	160 months
Remaining Amortization Period (months)	154 months
C-E MELPHALAN IPR&D [Member]
Product Rights [Line Items]
Historical Cost	7,700	7,700
Net Amount	7,700	7,700
MARQIBO distribution rights [Member]
Product Rights [Line Items]
Historical Cost	26,900	26,900
Accumulated Amortization	-4,225	-1,107
Net Amount	22,675	25,793
Full Amortization Period (months)	81 months
Remaining Amortization Period (months)	63 months
ZEVALIN distribution rights [Member] \| United States [Member]
Product Rights [Line Items]
Historical Cost	41,900	41,900
Accumulated Amortization	-27,134	-23,455
Net Amount	14,766	18,445
Full Amortization Period (months)	122 months
Remaining Amortization Period (months)	48 months
ZEVALIN distribution rights [Member] \| Ex-U.S. [Member]
Product Rights [Line Items]
Historical Cost	23,490	23,490
Accumulated Amortization	-7,402	-5,343
Foreign Currency Translation	-2,162	682
Net Amount	13,926	18,829
Full Amortization Period (months)	95 months
Remaining Amortization Period (months)	62 months
FUSILEV distribution rights [Member]
Product Rights [Line Items]
Historical Cost	16,778	16,778
Accumulated Amortization	-6,270	-4,821
Net Amount	10,508	11,957
Full Amortization Period (months)	84 months
Remaining Amortization Period (months)	40 months
FOLOTYN out-License [Member]
Product Rights [Line Items]
Historical Cost	27,900	27,900
Accumulated Amortization	-6,385	-3,662
Impairment	-1,023	-1,023
Net Amount	$20,492	$23,215
Full Amortization Period (months)	110 months
Remaining Amortization Period (months)	91 months

Balance_Sheet_Account_Detail_C2

Balance Sheet Account Detail - Components of Intangible Assets Net of Accumulated Amortization (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Product Rights [Line Items]
Impairment	$1,023	$1,023
FOLOTYN out-License [Member]
Product Rights [Line Items]
Impairment	$1,023	$1,023

Balance_Sheet_Account_Detail_E

Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Investment Holdings [Abstract]
2015	$25,937
2016	25,937
2017	25,937
2018	25,937
2019	23,332
2020 and thereafter	77,720
Intangible Assets, Net Total	$204,800

Balance_Sheet_Account_Detail_S5

Balance Sheet Account Detail - Schedule of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Foreign currency exchange translation effects	($202)	$104
Goodwill	18,195	18,501
ZEVALIN Ex-U.S. Distribution Rights [Member]
Goodwill [Line Items]
Acquisition	2,525	2,525
Allos Therapeutics, Inc. [Member]
Goodwill [Line Items]
Acquisition	5,346	5,346
Talon [Member]
Goodwill [Line Items]
Acquisition	$10,526	$10,526

Balance_Sheet_Account_Detail_S6

Balance Sheet Account Detail - Summary of Other Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Equity securities (see Note 11)	$8,501	$3,593
Supplies	234	190
2018 Convertible Notes issuance costs	2,171	3,432
Executive officer life insurance - cash surrender value	6,958	5,362
Other assets	$17,864	$12,577

Balance_Sheet_Account_Detail_S7

Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Trade payables	$8,994	$12,796
Accrued research and development expenses	5,423	6,433
Accrued selling, general and administrative expenses	10,154	8,870
Accrued rebates	41,782	28,893
Accrued product royalty	5,182	9,498
Allowance for returns	1,135	2,900
Accrued data and distribution fees	3,952	2,430
Accrued GPO administrative fees	3,222	2,327
Inventory management fee	1,110	616
Allowance for chargebacks	4,040	5,074
Accounts payable and other accrued liabilities	$84,994	$79,837

Balance_Sheet_Account_Detail_S8

Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Rebates and Chargebacks [Member]
Schedule of Investments [Line Items]
Balance as of December 31, 2012	$33,967	$26,176
Add: provisions (recovery)	76,636	63,609
(Less): credits or actual allowances	-64,781	-55,818
Balance as of December 31, 2013	45,822	33,967
Data and Distribution, GPO Fees, and Inventory Management Fees [Member]
Schedule of Investments [Line Items]
Balance as of December 31, 2012	5,373	14,149
Add: provisions (recovery)	21,330	19,067
(Less): credits or actual allowances	-18,419	-27,843
Balance as of December 31, 2013	8,284	5,373
Returns [Member]
Schedule of Investments [Line Items]
Balance as of December 31, 2012	2,900	5,056
Add: provisions (recovery)	-78	-2,034
(Less): credits or actual allowances	-1,687	-122
Balance as of December 31, 2013	$1,135	$2,900

Balance_Sheet_Account_Detail_S9

Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Accrued executive deferred compensation	$4,694	$3,949
Deferred rent (non-current portion)	364	366
Business acquisition liability	300	298
Other tax liabilities	730	1,352
Other long-term liabilities	$6,088	$5,965

GrosstoNet_Product_Sales_Recon

Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue, Net [Abstract]
Gross product sales	$284,685	$224,301	$383,817
Rebates and chargebacks	-76,636	-63,610	-91,059
Data, distribution and GPO administration fees	-21,330	-19,067	-32,793
Prompt pay discount	-260	-183	-4,814
Product returns allowance	78	2,034	-159
Product sales, net	$186,537	$143,475	$254,992

Net_Product_Sales_by_Geographi2

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers - Schedule of Net Product Sales by Geography (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Sales Information [Line Items]
Net product sales	$186,537	$143,475	$254,992
ZEVALIN [Member]
Sales Information [Line Items]
Net product sales	22,169	29,393	30,327
United States [Member]
Sales Information [Line Items]
Net product sales	177,979	133,462	245,697
Total International [Member]
Sales Information [Line Items]
Net product sales	8,558	10,013	9,295
Total International [Member] \| Europe [Member] \| ZEVALIN [Member]
Sales Information [Line Items]
Net product sales	3,357	3,953	3,113
Total International [Member] \| Asia Pacific [Member] \| ZEVALIN [Member]
Sales Information [Line Items]
Net product sales	$5,201	$6,060	$6,182
Geographic Concentration Risk [Member] \| Sales [Member]
Sales Information [Line Items]
Percentage of net product sales	100.00%	100.00%	100.00%
Geographic Concentration Risk [Member] \| Sales [Member] \| United States [Member]
Sales Information [Line Items]
Percentage of net product sales	95.40%	93.00%	96.40%
Geographic Concentration Risk [Member] \| Sales [Member] \| Total International [Member]
Sales Information [Line Items]
Percentage of net product sales	4.60%	7.00%	3.60%
Geographic Concentration Risk [Member] \| Sales [Member] \| Total International [Member] \| Europe [Member] \| ZEVALIN [Member]
Sales Information [Line Items]
Percentage of net product sales	1.80%	2.80%	1.20%
Geographic Concentration Risk [Member] \| Sales [Member] \| Total International [Member] \| Asia Pacific [Member] \| ZEVALIN [Member]
Sales Information [Line Items]
Percentage of net product sales	2.80%	4.20%	2.40%

Net_Product_Sales_by_Geographi3

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers - Schedule of Net Product Sales by Product Line (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Sales Information [Line Items]
Net product sales	$186,537	$143,475	$254,992
FUSILEV [Member]
Sales Information [Line Items]
Net product sales	105,608	68,397	204,253
FOLOTYN [Member]
Sales Information [Line Items]
Net product sales	47,556	44,370	20,412
ZEVALIN [Member]
Sales Information [Line Items]
Net product sales	22,169	29,393	30,327
MARQIBO [Member]
Sales Information [Line Items]
Net product sales	6,328	1,315
BELEODAQ [Member]
Sales Information [Line Items]
Net product sales	$4,876
Product Concentration Risk [Member] \| Sales [Member]
Sales Information [Line Items]
Percentage of net product sales	100.00%	100.00%	100.00%
Product Concentration Risk [Member] \| Sales [Member] \| FUSILEV [Member]
Sales Information [Line Items]
Percentage of net product sales	56.60%	47.70%	80.10%
Product Concentration Risk [Member] \| Sales [Member] \| FOLOTYN [Member]
Sales Information [Line Items]
Percentage of net product sales	25.50%	30.90%	8.00%
Product Concentration Risk [Member] \| Sales [Member] \| ZEVALIN [Member]
Sales Information [Line Items]
Percentage of net product sales	11.90%	20.50%	11.90%
Product Concentration Risk [Member] \| Sales [Member] \| MARQIBO [Member]
Sales Information [Line Items]
Percentage of net product sales	3.40%	0.90%
Product Concentration Risk [Member] \| Sales [Member] \| BELEODAQ [Member]
Sales Information [Line Items]
Percentage of net product sales	2.60%

Net_Product_Sales_by_Geographi4

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers - Summary of Customers Representing 10% or More of Gross Product Sales (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue, Major Customer [Line Items]
Gross product sales	$284,685	$224,301	$383,817
Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS) [Member]
Revenue, Major Customer [Line Items]
Gross product sales	115,079	79,497	101,712
McKesson Corporation and its affiliates [Member]
Revenue, Major Customer [Line Items]
Gross product sales	93,656	44,350	89,046
Integrated Commercialization Solutions, Inc. (ICS) [Member]
Revenue, Major Customer [Line Items]
Gross product sales		35,548	74,461
Cardinal Health, Inc. and its affiliates [Member]
Revenue, Major Customer [Line Items]
Gross product sales			60,259
All Other Customers [Member]
Revenue, Major Customer [Line Items]
Gross product sales	$75,950	$64,906	$58,339
Customer Concentration Risk [Member] \| Gross Product Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	100.00%	100.00%	100.00%
Customer Concentration Risk [Member] \| Gross Product Sales [Member] \| Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS) [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	40.00%	35.40%	26.50%
Customer Concentration Risk [Member] \| Gross Product Sales [Member] \| McKesson Corporation and its affiliates [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	32.10%	19.80%	23.20%
Customer Concentration Risk [Member] \| Gross Product Sales [Member] \| Integrated Commercialization Solutions, Inc. (ICS) [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales		15.80%	19.40%
Customer Concentration Risk [Member] \| Gross Product Sales [Member] \| Cardinal Health, Inc. and its affiliates [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales			15.70%
Customer Concentration Risk [Member] \| Gross Product Sales [Member] \| All Other Customers [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	27.90%	29.00%	15.20%

Net_Product_Sales_by_Geographi5

Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers - Summary of Customers Representing 10% or More of Gross Product Sales (Parenthetical) (Detail) (Customer Concentration Risk [Member], Gross Product Sales [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue, Major Customer [Line Items]
Percentage of gross product sales	100.00%	100.00%	100.00%
Integrated Commercialization Solutions, Inc. (ICS) [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales		15.80%	19.40%
Cardinal Health, Inc. and its affiliates [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales			15.70%
Maximum [Member] \| Integrated Commercialization Solutions, Inc. (ICS) [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	10.00%
Maximum [Member] \| Cardinal Health, Inc. and its affiliates [Member]
Revenue, Major Customer [Line Items]
Percentage of gross product sales	10.00%	10.00%

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009
	Plans	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock incentive plans	1
Estimated forfeiture rate	8.00%	8.00%	5.00%
Exercise of Issued Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	11,400,000
Weighted average period to recognize compensation expense	2 years 6 months 15 days
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	4,900,000
Weighted average period to recognize compensation expense	2 years 9 months 18 days
Upon Termination of Employment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based award vest	25.00%
Restricted stock exercised period	90 days
In the Event of Optionee's Death, Disability or Retirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock exercised period	365 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock vesting period	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock vesting period	3 years
2009 Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under incentive plan	10,000,000
Increased number of common stock shares				2,500,000
Issuance of common stock				30.00%
Incentive awards available for grant	9,500,000
2009 Incentive Award Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price fair value	100.00%
2013 Stock Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive awards available for grant	50,000
Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under incentive plan	4,400,000
Incentive awards available for grant	10,000,000
Percentage of common stock purchase price	15.00%
Purchase Plan offering period	6 months
Maximum number of common stock shares available for purchase per participant	50,000
Maximum number of common stock value available for purchase per participant	25,000
Increase in number of shares of common stock available for issuance under the purchase plan	1,000,000

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$11,809	$12,779	$14,884
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	10,053	10,762	13,041
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$1,756	$2,017	$1,843

StockBased_Compensation_Fair_V

Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected option life (in years)	4 years 11 months 12 days	4 years 11 months 12 days	4 years 6 months
Risk-free interest rate, Minimum	0.58%	0.35%	0.34%
Risk-free interest rate, Maximum	1.52%	0.78%	0.51%
Volatility, Minimum	48.90%	58.30%	64.20%
Volatility, Maximum	62.10%	71.50%	73.60%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average grant-date fair value per stock option	$3.49	$4.66	$6.20

StockBased_Compensation_Fair_V1

Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	4 years 11 months 12 days	4 years 11 months 12 days	4 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	10 years	10 years	10 years

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Outstanding, Beginning Balance	11,329,218	10,399,265	10,185,521
Weighted-Average Exercise Price/Share, Outstanding, Beginning Balance	$7.10	$6.57	$5.46
Number of Shares, Granted	2,576,292	2,041,300	1,821,915
Number of Shares, Exercised	-485,260	-825,884	-1,287,430
Number of Shares, Forfeited	-557,109	-202,882	-316,825
Number of Shares, Expired	-214,039	-82,581	-3,916
Number of Shares, Outstanding, Ending Balance	12,649,102	11,329,218	10,399,265
Number of Shares, Vested (exercisable) - December 31, 2014	9,134,760
Weighted-Average Exercise Price/Share, Granted	$7.60	$8.92	$11.57
Number of Shares, Vested (exercisable) - December 31, 2014	3,514,342
Weighted-Average Exercise Price/Share, Exercised	$4.77	$4.40	$4.52
Weighted-Average Exercise Price/Share, Forfeited	$9.65	$8.22	$7.93
Weighted-Average Exercise Price/Share, Expired	$10.70	$8.91	$7.69
Weighted-Average Exercise Price/Share Outstanding, Ending Balance	$7.12	$7.10	$6.57
Weighted-Average Exercise Price/Share, Vested (exercisable) - December 31, 2013	$6.62
Weighted-Average Exercise Price/Share, Unvested (unexercisable) - December 31, 2013	$8.42
Weighted-Average Remaining Contractual Term (Years), Outstanding	6 years 7 months 10 days
Weighted-Average Remaining Contractual Term (Years), Vested (exercisable) - December 31, 2014	5 years 7 months 28 days
Weighted-Average Remaining Contractual Term (Years), Unvested (unexercisable) - December 31, 2014	9 years 26 days
Stock options exercised, Intrinsic value	$1,629	$3,435	$11,500
Aggregate Intrinsic Value	11,679
Aggregate Intrinsic Value, Vested (exercisable) - December 31, 2014	11,678
Aggregate Intrinsic Value, Unvested (unexercisable) - December 31, 2014	$766

StockBased_Compensation_Summar2

Stock-Based Compensation - Summary of Stock Option Grants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Granted Stock Options Outstanding	12,649,102
Weighted-Average Remaining Contractual Life (Years)	6 years 7 months 10 days
Weighted-Average Exercise Price	$7.12
Granted Stock Options Exercisable	9,134,760
Weighted-Average Exercise Price	$6.62
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Range lower limit	$0.92
Exercise Price, Range upper limit	$3.15
Granted Stock Options Outstanding	1,135,594
Weighted-Average Remaining Contractual Life (Years)	3 years 5 months 19 days
Weighted-Average Exercise Price	$2.19
Granted Stock Options Exercisable	1,135,594
Weighted-Average Exercise Price	$2.19
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Range lower limit	$3.16
Exercise Price, Range upper limit	$4.95
Granted Stock Options Outstanding	1,673,317
Weighted-Average Remaining Contractual Life (Years)	4 years 10 months 21 days
Weighted-Average Exercise Price	$4.24
Granted Stock Options Exercisable	1,673,317
Weighted-Average Exercise Price	$4.24
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Range lower limit	$4.96
Exercise Price, Range upper limit	$6.90
Granted Stock Options Outstanding	2,708,119
Weighted-Average Remaining Contractual Life (Years)	4 years 5 months 1 day
Weighted-Average Exercise Price	$6.27
Granted Stock Options Exercisable	2,701,899
Weighted-Average Exercise Price	$6.27
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Range lower limit	$6.91
Exercise Price, Range upper limit	$8.99
Granted Stock Options Outstanding	4,539,130
Weighted-Average Remaining Contractual Life (Years)	8 years 4 months 28 days
Weighted-Average Exercise Price	$7.86
Granted Stock Options Exercisable	1,983,129
Weighted-Average Exercise Price	$8.09
Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Range lower limit	$9
Exercise Price, Range upper limit	$16.32
Granted Stock Options Outstanding	2,592,942
Weighted-Average Remaining Contractual Life (Years)	8 years 2 months 16 days
Weighted-Average Exercise Price	$10.75
Granted Stock Options Exercisable	1,640,821
Weighted-Average Exercise Price	$10.94

StockBased_Compensation_Summar3

Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Restricted Stock Awards, Unvested, Beginning Balance	1,007,119	1,034,604	952,525
Number of Restricted Stock Awards, Granted	581,194	523,800	586,639
Number of Restricted Stock Awards, Vested	-578,985	-501,660	-472,160
Number of Restricted Stock Awards, Forfeited	-185,111	-49,625	-32,400
Number of Restricted Stock Awards, Unvested, Ending Balance	824,217	1,007,119	1,034,604
Weighted Average Fair Value per Share at Grant Date, Beginning Balance	$10.09	$11	$10.11
Weighted Average Fair Value per Share at Grant Date, Granted	$7.52	$8.74	$11.76
Weighted Average Fair Value per Share at Grant Date, Vested	$10.24	$9.72	$10.26
Weighted Average Fair Value per Share at Grant Date, Forfeited	$9.88	$10.60	$9.57
Weighted Average Fair Value per Share at Grant Date, Ending Balance	$8.22	$10.09	$11

StockBased_Compensation_Fair_V2

Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Restricted stock expense	$3,830	$4,202	$6,500

StockBased_Compensation_Issued

Stock-Based Compensation - Issued Shares of Common Stock (Detail) (401(k) Plan [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
401(k) Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued	133,734	99,359	56,254
Match contribution value	$1,028	$860	$691

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2003	Dec. 31, 2014	Dec. 31, 2013	Jun. 13, 2011
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Preferred stock, shares authorized		5,000,000	5,000,000
Number of common shares authorized		175,000,000	175,000,000
New replacement rights agreement extended date		13-Dec-20
Percentage of outstanding shares acquired to exercise preferred share rights		15.00%
Transfer of assets or earnings power		50.00%
Common stock trading price per share	$12
Percentage of preferred stock liquidation preference common stock		120.00%
Shares of common stock issuable upon conversion or exercise of rights granted		24,900,000
Outstanding warrants expire on varying dates		Dec-15
Maximum [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Number of common shares authorized				175,000,000
Minimum [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Number of common shares authorized				100,000,000
Series B Junior Participating Preferred Stock [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Preferred stock, shares authorized		1,500,000	1,500,000
Preferred stock issued		0	0
Convertible preferred stock outstanding		0	0
Series E Convertible Voting Preferred Stock [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Preferred stock, shares authorized		2,000	2,000
Preferred stock issued	2,000	20	20
Preferred stock converted into common stock	4,000,000	40,000	40,000
Convertible preferred stock outstanding		20	20
Number of trading days consider for option to redeem preferred stock	20 days
Dividends payable	$0
Cash proceeds from exchange of preferred stock	$20,000,000

Stockholders_Equity_Shares_of_

Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail)	Dec. 31, 2014
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	24,880,602
Series E Convertible Voting Preferred Stock [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	40,000
2018 Convertible Notes [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	11,400,000
Employee Stock Option [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	12,649,102
Management Incentive Plan Restricted Stock Units [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	346,500
Exercise of Issued Warrants [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Total common shares	445,000

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Weighted Average Exercise Price, Granted		$7.51
Weighted Average Exercise Price, Beginning Balance	$6.39	$5.45	$5.04
Weighted Average Exercise Price, Exercised			$1.79
Weighted Average Exercise Price, Ending Balance	$6.39	$6.39	$5.45
Weighted Average Exercise Price, Exercisable	$6.39
Exercise of Issued Warrants [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Number of Shares, Outstanding Beginning		395,000	445,000
Number of Shares, Granted		50,000
Number of Shares, Exercised			-50,000
Number of Shares, Outstanding Ending	445,000	445,000	395,000
Exercisable, Number of Shares Outstanding	445,000

Net_Loss_Income_Per_Share_Comp

Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net (loss) income	($2,976)	($11,539)	($3,563)	($27,641)	($39,166)	($7,812)	($9,721)	($5,435)	($45,719)	($62,134)	$94,201
Weighted average shares-basic									64,708,163	60,729,128	58,588,916
Net (loss) income per share-basic	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.61
Weighted average shares-diluted									64,708,163	60,729,128	64,637,256
Net (loss) income per share-diluted	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.46

Net_Loss_Income_Per_Share_Sche

Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net income (loss)	($2,976)	($11,539)	($3,563)	($27,641)	($39,166)	($7,812)	($9,721)	($5,435)	($45,719)	($62,134)	$94,201
Weighted-Average Shares Outstanding (Denominator), Basic									64,708,163	60,729,128	58,588,916
Dilutive preferred shares											40,000
Dilutive common stock options											4,749,299
Incremental common stock assumed issued on exercise of in-the-money warrants											224,437
Unvested restrictive stock awards											1,034,604
Weighted-Average Shares Outstanding (Denominator), Diluted									64,708,163	60,729,128	64,637,256
Net Income Per Share, Basic	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.61
Net Income Per Share, Diluted	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.46

Net_Loss_Income_Per_Share_Sche1

Net (Loss) Income Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	14,560,119	4,486,160
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	40,000	40,000
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	120,702	160,816
2018 Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	11,401,284	343,600
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	2,173,916	2,934,625
Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount	824,217	1,007,119

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets:
Deferred compensation investments, including life insurance cash surrender value	$6,958,000	$5,361,000
Total Assets	87,168,000	112,820,000
Liabilities:
Deferred executive compensation liability	4,694,000	3,949,000
Deferred development costs	15,785,000	17,742,000
Ligand Contingent Consideration	4,901,000	4,000,000
Talon CVR	2,379,000	4,329,000
Corixa Liability	62,000
Total Liabilities	27,821,000	30,020,000
Bank CDs [Member]
Assets:
Marketable securities, fair value	244,000	410,000
Money Market Funds [Member]
Assets:
Marketable securities, fair value	66,945,000	100,395,000
Equity Securities [Member]
Assets:
Marketable securities, fair value	9,959,000	3,593,000
Mutual Funds [Member]
Assets:
Marketable securities, fair value	3,062,000	3,061,000
Level 1 [Member]
Assets:
Total Assets	9,959,000	3,593,000
Level 1 [Member] \| Equity Securities [Member]
Assets:
Marketable securities, fair value	9,959,000	3,593,000
Level 2 [Member]
Assets:
Deferred compensation investments, including life insurance cash surrender value	6,958,000	5,361,000
Total Assets	77,209,000	109,227,000
Liabilities:
Deferred executive compensation liability	4,694,000	3,949,000
Total Liabilities	4,694,000	3,949,000
Level 2 [Member] \| Bank CDs [Member]
Assets:
Marketable securities, fair value	244,000	410,000
Level 2 [Member] \| Money Market Funds [Member]
Assets:
Marketable securities, fair value	66,945,000	100,395,000
Level 2 [Member] \| Mutual Funds [Member]
Assets:
Marketable securities, fair value	3,062,000	3,061,000
Level 3 [Member]
Liabilities:
Deferred development costs	15,785,000	17,742,000
Ligand Contingent Consideration	4,901,000	4,000,000
Talon CVR	2,379,000	4,329,000
Corixa Liability	62,000
Total Liabilities	$23,127,000	$26,071,000

Fair_Value_Measurements_Activi

Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance			$14,520
Ending Balance	23,127	26,071	14,520
Deferred Development Costs [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfers in (out) of Level 3	-1,957	5,509
Deferred Payment Contingency [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfers in (out) of Level 3		-2,287
Ligand Contingent Consideration [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfers in (out) of Level 3	901	4,000
Talon CVR [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfers in (out) of Level 3	-1,950	4,329
Corixa Liability [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfers in (out) of Level 3	$62

Business_Combinations_and_Cont2

Business Combinations and Contingent Consideration - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Jul. 17, 2013	Dec. 31, 2013	Jul. 31, 2013
Business Acquisition [Line Items]
Milestone payments methods	If all sales and regulatory approval milestones are achieved, as summarized below: b" $5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year b" $10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year b" $25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year b" $50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year b" $100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year b" $5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion
Goodwill	$10,500,000
Net assets acquired	44,100,000
Total purchase consideration	33,600,000
License fees received	3,000,000
Royalties payout percentage on our future net sales of licensed products	20.00%
Ligand Contingent Consideration	4,901,000		4,000,000
IPR&D [Member]
Business Acquisition [Line Items]
Estimated cash flow period	10 years
Estimated cash flow discount rate	25.00%
Milestone Payments [Member]
Business Acquisition [Line Items]
Milestone net sales achievement	66,000,000	5,000,000
Milestone net sales achievement		30,000,000
Ligand Contingent Consideration	6,000,000
Milestone Payment One [Member]
Business Acquisition [Line Items]
Milestone net sales achievement		10,000,000
Milestone net sales achievement		60,000,000
Milestone Payment Two [Member]
Business Acquisition [Line Items]
Milestone net sales achievement		25,000,000
Milestone net sales achievement		100,000,000
Milestone Payment Three [Member]
Business Acquisition [Line Items]
Milestone net sales achievement		50,000,000
Milestone net sales achievement		200,000,000
Milestone Payment Four [Member]
Business Acquisition [Line Items]
Milestone net sales achievement		100,000,000
Milestone net sales achievement		400,000,000
Menadione Topical Lotion [Member]
Business Acquisition [Line Items]
Milestone net sales achievement		5,000,000
Talon Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Additional shares business acquisition date	17-Jul-13
Cash consideration	11,300,000
Shares issued in acquisition		3
Common stock value, per share	$8.77
Common stock value assigned		26,300,000
Contingent value rights future cash payments		195,000,000		195,000,000
Contingent value rights valuation description	The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs - see Note 2 (xiii)).
Contingent value rights discount rate		25.00%
Estimated fair value of acquisition		6,500,000
Goodwill	10,526,000
Net assets acquired	33,574,000
Talon Therapeutics, Inc. [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Contingent value rights expected rate		50.00%
Talon Therapeutics, Inc. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Contingent value rights expected rate		100.00%
Allos Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Total purchase consideration	205,200,000
Ligand Contingent Consideration	$0

Business_Combinations_and_Cont3

Business Combinations and Contingent Consideration - Change in Fair Value of Contingent Consideration Related to Acquisitions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Talon Therapeutics, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Fair value, Beginning Balance	$4,329
Fair value adjustment for the year ended December 31, 2014	-1,950
Fair value, Ending Balance	2,379
Ligand Pharmaceuticals Inc [Member]
Business Acquisition, Contingent Consideration [Line Items]
Fair value, Beginning Balance	4,000
Fair value adjustment for the year ended December 31, 2014	901
Fair value, Ending Balance	$4,901

Business_Combinations_and_Cont4

Business Combinations and Contingent Consideration - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Business Acquisition [Line Items]
Net assets acquired	$44,100
Goodwill	10,500
Total purchase consideration	33,600
Captisol-enabled, propylene glycol-free melphalan rights [Member]
Business Acquisition [Line Items]
Total purchase consideration	7,700
Talon Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Cash and equivalents	131
Inventory	611
Prepaid expenses and other current assets	109
Property and equipment	30
Identifiable intangible assets	44,500
Total assets acquired	45,381
Accounts payable & accrued liabilities	5,231
Deferred tax liability	6,576
Total liabilities assumed	11,807
Net assets acquired	33,574
Goodwill	10,526
IPR&D [Member] \| Captisol-enabled, propylene glycol-free melphalan rights [Member]
Business Acquisition [Line Items]
Total purchase consideration	$7,700

Business_Combinations_and_Cont5

Business Combinations and Contingent Consideration - Amortization Period for such Intangible Assets Acquired (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Talon Therapeutics, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets	44,500
Developed technology - MARQIBO for ALL [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization Period	81 months
Developed technology - MARQIBO for ALL [Member] \| Talon Therapeutics, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets	26,900
IPR&D - MARQIBO for NHL and other potential indications [Member] \| Talon Therapeutics, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets	17,600

Business_Combinations_and_Cont6

Business Combinations and Contingent Consideration - Acquisition-Date Fair Value of Consideration Transferred (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Ligand Contingent Consideration	$4,901,000	$4,000,000
Total purchase consideration	33,600,000
Captisol-enabled, propylene glycol-free melphalan rights [Member]
Business Acquisition [Line Items]
Cash consideration	3,000,000
Ligand Contingent Consideration	4,700,000
Total purchase consideration	$7,700,000

OutLicense_of_Marqibo_Zevalin_2

Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory - Additional Information (Detail) (CASI Out-License [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
CASI Out-License [Member]
Other Commitments [Line Items]
License agreement description	Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues securities.
License agreement expiration date	17-Sep-19
License fees and service revenue to be recognized	$10.10

OutLicense_of_Marqibo_Zevalin_3

Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Detail) (CASI Out-License [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Sep. 17, 2014
Other Commitments [Line Items]
Total consideration received	$9,959
Secured Promissory Note Due March 17, 2016 [Member]
Other Commitments [Line Items]
Total consideration received	1,310
Common Stock [Member]
Other Commitments [Line Items]
Total consideration received	$8,649

OutLicense_of_Marqibo_Zevalin_4

Out-License of Marqibo, Zevalin, & C-E Melphalan in China Territory - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Parenthetical) (Detail) (USD $)	0 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Sep. 17, 2014	Dec. 31, 2014	Dec. 31, 2013
Other Commitments [Line Items]
Equity securities		$8,501,000	$3,593,000
Secured Promissory Note Due March 17, 2016 [Member]
Other Commitments [Line Items]
Debt instrument face value	1,500,000
CASI Out-License [Member]
Other Commitments [Line Items]
Shares received	5.4
Stock price on the NASDAQ Capital Market	$1.60
CASI Out-License [Member] \| Secured Promissory Note Due March 17, 2016 [Member]
Other Commitments [Line Items]
Debt instrument face value	$1,500,000
Debt instrument maturity date	17-Mar-16
Debt instrument coupon rate	0.50%

Revolving_Line_of_Credit_Addit

Revolving Line of Credit - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Credit agreement revolving line of credit facility	$50,000,000
Interest expense	$3,227,000	$1,200,000	$495,000

Convertible_Senior_Notes_Addit

Convertible Senior Notes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Line Items]
Common shares sold	$66,000	$64,000
2018 Convertible Notes [Member]
Debt Disclosure [Line Items]
Estimated aggregate fair value	113,200,000
Principal amount	120,000,000
2.75% Convertible Senior Notes Due 2018 [Member]
Debt Disclosure [Line Items]
Sale of convertible notes, principal amount	120,000,000
Conversion rate, shares	95
Conversion rate, price per share	$1,000
Common shares converted value	11,400,000
Money conversion price per share	$10.53
Interest rate	2.75%
Convertible senior notes maturity date	15-Dec-18
Net proceeds from convertible notes	115,400,000
Professional fee	4,600,000
Additional paid-in capital	13,100,000
Strike price per share	$14.03
Common shares sold	11,400,000
Threshold percentage of conversion price	130.00%
Convertible senior notes trading price	$1,000
Percentage of product of last reported sale price of common stock	98.00%
Convertible senior notes conversion description	Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under any of the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of (i) the last reported sale price of our common stock on such trading day and (ii) the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; and (4) at any time prior to our stockholdersb approval to settle the 2018 Convertible Notes in our common shares and/or cash. On and after June 15, 2018, and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes.
2.75% Convertible Senior Notes Due 2018 [Member] \| Minimum [Member]
Debt Disclosure [Line Items]
Debt convertible trading days	20 days
Debt convertible consecutive trading days	5 days
2.75% Convertible Senior Notes Due 2018 [Member] \| Maximum [Member]
Debt Disclosure [Line Items]
Debt convertible consecutive trading days	30 days

Convertible_Senior_Notes_Carry

Convertible Senior Notes - Carrying Value of 2018 Convertible Notes (Detail) (2018 Convertible Notes [Member], USD $)	Dec. 31, 2014
2018 Convertible Notes [Member]
Debt Instrument [Line Items]
Principal amount	$120,000,000
(Less): Unamortized debt discount (amortized through December 2018)	-23,702,000
December 31, 2014 carrying value	$96,298,000

Convertible_Senior_Notes_Compo

Convertible Senior Notes - Components of Total Interest Expense, Net Recognized (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Equity Method Investments And Cost Method Investments [Abstract]
Contractual coupon interest expense	$3,300	$73
Amortization of debt issuance costs	599	101
Accretion of debt discount	4,818	43
Total	$8,717	$217
Effective interest rate	8.66%	8.59%

Mundipharma_Agreement_Addition

Mundipharma Agreement - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	29-May-13	Sep. 30, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Company determined development payment	$218,399,000	$194,639,000	$186,933,000
Deferred development cost					12,300,000
Mundipharma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Company determined development payment				7,000,000
Development cost liability	15,800,000
Maximum [Member] \| Regulatory [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	16,000,000
Maximum [Member] \| Commercial progress and sales-dependent [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	$107,000,000

Mundipharma_Agreement_Schedule

Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Accrued Liabilities [Line Items]
Beginning Balance		$3,119
Ending Balance	1,141	3,119
FOLOTYN [Member]
Schedule Of Accrued Liabilities [Line Items]
Beginning Balance	17,742
(Less): Expenses incurred in 2014	-1,957
Ending Balance	15,785
FOLOTYN [Member] \| Drug Development Liability Current [Member]
Schedule Of Accrued Liabilities [Line Items]
Beginning Balance	3,119
Transfer from long term to current in 2014	-21
(Less): Expenses incurred in 2014	-1,957
Ending Balance	1,141
FOLOTYN [Member] \| Drug Development Liability Long Term [Member]
Schedule Of Accrued Liabilities [Line Items]
Beginning Balance	14,623
Transfer from long term to current in 2014	21
Ending Balance	$14,644

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail)

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Share data in Millions, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

31-May-06

Dec. 31, 2014

Dec. 17, 2014

Jun. 27, 2014

Apr. 30, 2012

Dec. 31, 2014

Dec. 31, 2013

Jul. 31, 2013

Jul. 17, 2013

Jan. 31, 2012

Feb. 28, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Oct. 31, 2008

Feb. 28, 2010

Dec. 31, 2014

Nov. 30, 2014

Feb. 28, 2014

Dec. 31, 2014

USD ($)

FOLOTYN [Member]

ZEVALIN [Member]

Talon Therapeutics, Inc. [Member]

SPI-2012 [Member]

Poziotinib [Member]

Minimum [Member]

Maximum [Member]

Nevada [Member]

California [Member]

Allergan [Member]

TopoTarget [Member]

Nippon Kayaku [Member]

USD ($)

Licensing Agreements [Member]

USD ($)

Licensing Agreements [Member]

FOLOTYN [Member]

USD ($)

FOLOTYN [Member]

Principal executive office [Member]

Research and development facility [Member]

USD ($)

EUR (€)

USD ($)

Subsequent Event [Member]

USD ($)

Country

USD ($)

Long-term Purchase Commitment [Line Items]

Facility lease, non-cancelable operating lease expiring date

31-May-19

Rental expense

$1,900,000

$1,200,000

$900,000

Milestone payments

16,000,000

5,000,000

Potential milestone achievement

100,000

238,000,000

278,000,000

Minimum number of countries outside U.S. approved ZEVALIN for treatment

Fees paid to Bayer for acquiring licensing rights

19,000,000

Licensing Agreement Contractual Term

P15Y

Up-front non-refundable payment

500,000

41,500,000

license fee and service revenue

3,000,000

Percentage of royalty on net sales

20.00%

Amount receivable on approval of oral form of FUSILEV

200,000

Percentage of royalty on annual worldwide sales under condition one

20.00%

8.00%

Percentage of royalty on annual worldwide sales under condition two

9.00%

Percentage of royalty on annual worldwide sales under condition three

11.00%

Amount of annual worldwide sales on which royalty is payable under condition one

150,000,000

Amount of annual worldwide sales on which royalty is payable under condition two

150,000,000

300,000,000

Amount of annual worldwide sales on which royalty is payable under condition three

300,000,000

Milestone payments related to sales

107,000,000

358,000,000

Additional license fees

66,000,000

Percentage of royalties on net sale of licensed products

20.00%

Acquisition-related contingent obligations

2,441,000

8,329,000

2,400,000

4,300,000

4,900,000

4,000,000

Contingent value rights future cash payments

195,000,000

Upfront fee

15,000,000

Payment related to agreement

10,000,000

Payment on achievement of commercialization milestones

126,000,000

Upfront fee

30,000,000

Percentage of development cost

70.00%

Percentage of development cost that is funded by TopoTarget for joint development plan

30.00%

Additional payments based on the achievement of certain development

10,000,000

Shares of common stock, issued

Aggregate payout value

17,800,000

Second milestone payment

25,000,000

Deferrals and contributions

$4,700,000

$3,900,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$1,210
2016	1,150
2017	1,120
2018	1,155
2019	460
Operating lease future minimum payments, Total	$5,095

Income_Taxes_Components_of_Los

Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
United States	($37,327)	($30,437)	$82,165
Foreign	-6,205	-6,199	-2,235
(Loss) income before income taxes	($43,533)	($36,636)	$79,930

Income_Taxes_Provision_Benefit

Income Taxes - Provision (Benefit) for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$1,529	($8,357)	$16,222
State	126	-691	3,412
Foreign	29
Current, total	1,684	-9,048	19,634
Deferred:
Federal	495	36,183	-24,013
State	7	-1,637	-9,892
Foreign	0	0	0
Deferred, total	502	34,546	-33,905
Provision (Benefit) for income taxes	$2,186	$25,498	($14,271)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income tax provision related to prior year federal net operating losses	$1,500,000
Valuation allowance	45,983,000	49,586,000
Increase (decrease) in valuation allowance due to deferred tax assets	-3,600,000	47,800,000
Research and development tax credits	9,045,000	8,066,000
Unrecognized tax benefits, if recognized, would affect the effective tax rate	700,000	300,000	5,200,000
Talon [Member]
Income Taxes [Line Items]
Increase (decrease) in valuation allowance due to deferred tax assets	-17,200,000
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	106,100,000
Net operating loss carryforwards expiration year	2018
Research and development tax credits	10,200,000
Research and development tax credits beginning expiration year	2027
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	114,400,000
Net operating loss carryforwards expiration year	2015
Research and development tax credits	2,400,000
Foreign [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$9,100,000
Net operating loss carryforwards expiration year	2022

Income_Taxes_Income_Tax_Provis

Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Tax provision (benefit) computed at the federal statutory rate	($15,236)	($12,822)	$27,975
State tax, net of federal benefit	66	-246	2,442
Expired tax attributes	0	0	0
Research credits	-2,134	-2,254	-2,129
Benefits from credit study			-4,148
Common stock warrant liability	0	0	0
Transaction costs	-11	880	1,497
Officers compensation	1,895	2,178	2,908
Stock based compensation	299	501	134
Permanent items and other	21,742	-1,080	2,111
Domestic manufacturing deduction	-630	767	-1,262
Tax differential on foreign earnings	1,570	1,123	382
Change in tax rate	-519	-283	338
Valuation allowance	-4,856	36,734	-44,519
Provision (Benefit) for income taxes	$2,186	$25,498	($14,271)

Income_Taxes_Components_of_Com

Income Taxes - Components of Company's Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carry forwards	$40,505	$46,482
Research credits	9,045	8,066
Stock based compensation	3,703	3,486
Deferred revenue	1,893	58
Development costs	5,950	6,495
Returns and allowances	4,161	3,117
Other, net	9,082	5,551
Total deferred tax assets before valuation allowance	74,339	73,255
Valuation allowance	-45,983	-49,586
Total deferred tax assets	28,356	23,669
Deferred tax liabilities:
Basis difference in debt	-907	-1,082
Depreciation and amortization differences	-34,088	-28,096
Net deferred tax (liability) asset	($6,639)	($5,509)

Income_Taxes_Summary_of_Unreco

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Balance at beginning of year	$2,212	$5,482	$3,928
Adjustments related to prior year tax positions	-915	-200	-527
Increases related to current year tax positions	647	648	2,515
Decreases due to settlements		-1,227	-434
Decreases related to prior year tax positions		-2,491
Balance at end of year	$1,944	$2,212	$5,482

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$51,861	$47,990	$46,855	$40,124	$41,516	$42,439	$33,232	$38,667	$186,830	$155,854	$267,707
Operating loss	-1,632	-4,127	-1,396	-24,414	-6,512	-13,287	-12,529	-6,457	-31,569	-38,785	80,774
Net loss	($2,976)	($11,539)	($3,563)	($27,641)	($39,166)	($7,812)	($9,721)	($5,435)	($45,719)	($62,134)	$94,201
Net loss per share, basic	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.61
Net loss per share, diluted	($0.05)	($0.18)	($0.06)	($0.44)	($0.63)	($0.13)	($0.16)	($0.09)	($0.71)	($1.02)	$1.46

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$206	$228	$471
Additions (Recovery) to Bad Debt Expense	-85	11	-128
Charged to Other Accounts	0	0	0
Deductions	-1	-33	-115
Balance at End of Period	$120	$206	$228